ZA954570B - Conjugates of methyltrithio antitumor agents and intermediates for their synthesis - Google Patents

Conjugates of methyltrithio antitumor agents and intermediates for their synthesis

Info

Publication number: ZA954570B
Authority: ZA; South Africa
Prior art keywords: conjugates; carrier; synthesis; intermediates; well
Prior art date: 1994-06-03

Application number

ZA954570A

Other languages

English (en)

Inventor

Philip Ross Hamann

Lois Hinman

Irwin Hollander

Ryan Holcomb

William Hallett

Hwei-Ru Tsou

Martin J Weiss

Original Assignee

American Cyanamid Co

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

1994-06-03

Filing date

1995-06-02

Publication date

1996-05-22

Family has litigation

First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=22962074&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=ZA954570(B) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.

1995-06-02 Application filed by American Cyanamid Co filed Critical American Cyanamid Co

1996-05-22 Publication of ZA954570B publication Critical patent/ZA954570B/xx

Links

230000015572 biosynthetic process Effects 0.000 title abstract 2
238000003786 synthesis reaction Methods 0.000 title abstract 2
239000002246 antineoplastic agent Substances 0.000 title 1
239000000543 intermediate Substances 0.000 title 1
-1 methyltrithio Chemical group 0.000 title 1
239000003242 anti bacterial agent Substances 0.000 abstract 2
230000000259 anti-tumor effect Effects 0.000 abstract 2
229940088710 antibiotic agent Drugs 0.000 abstract 2
229940079593 drug Drugs 0.000 abstract 2
239000003814 drug Substances 0.000 abstract 2
229930189413 Esperamicin Natural products 0.000 abstract 1
206010028980 Neoplasm Diseases 0.000 abstract 1
HXCHCVDVKSCDHU-LULTVBGHSA-N calicheamicin Chemical compound C1[C@H](OC)[C@@H](NCC)CO[C@H]1O[C@H]1[C@H](O[C@@H]2C\3=C(NC(=O)OC)C(=O)C[C@](C/3=C/CSSSC)(O)C#C\C=C/C#C2)O[C@H](C)[C@@H](NO[C@@H]2O[C@H](C)[C@@H](SC(=O)C=3C(=C(OC)C(O[C@H]4[C@@H]([C@H](OC)[C@@H](O)[C@H](C)O4)O)=C(I)C=3C)OC)[C@@H](O)C2)[C@@H]1O HXCHCVDVKSCDHU-LULTVBGHSA-N 0.000 abstract 1
229930195731 calicheamicin Natural products 0.000 abstract 1
239000000969 carrier Substances 0.000 abstract 1
150000001875 compounds Chemical class 0.000 abstract 1
150000002019 disulfides Chemical class 0.000 abstract 1
239000012634 fragment Substances 0.000 abstract 1
239000003102 growth factor Substances 0.000 abstract 1
238000000034 method Methods 0.000 abstract 1
239000008194 pharmaceutical composition Substances 0.000 abstract 1
230000003389 potentiating effect Effects 0.000 abstract 1
102000004169 proteins and genes Human genes 0.000 abstract 1
108090000623 proteins and genes Proteins 0.000 abstract 1
150000003431 steroids Chemical class 0.000 abstract 1
230000008685 targeting Effects 0.000 abstract 1

Classifications

- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
- A61K47/6801—Drug-antibody or immunoglobulin conjugates defined by the pharmacologically or therapeutically active agent
- A61K47/6803—Drugs conjugated to an antibody or immunoglobulin, e.g. cisplatin-antibody conjugates
- A61K47/6807—Drugs conjugated to an antibody or immunoglobulin, e.g. cisplatin-antibody conjugates the drug or compound being a sugar, nucleoside, nucleotide, nucleic acid, e.g. RNA antisense
- A61K47/6809—Antibiotics, e.g. antitumor antibiotics anthracyclins, adriamycin, doxorubicin or daunomycin
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/62—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being a protein, peptide or polyamino acid
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents

Landscapes

Health & Medical Sciences (AREA)
Bioinformatics & Cheminformatics (AREA)
Engineering & Computer Science (AREA)
Life Sciences & Earth Sciences (AREA)
Chemical & Material Sciences (AREA)
Medicinal Chemistry (AREA)
Animal Behavior & Ethology (AREA)
Pharmacology & Pharmacy (AREA)
General Health & Medical Sciences (AREA)
Public Health (AREA)
Veterinary Medicine (AREA)
Epidemiology (AREA)
Immunology (AREA)
Molecular Biology (AREA)
Biochemistry (AREA)
Proteomics, Peptides & Aminoacids (AREA)
Organic Chemistry (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
General Chemical & Material Sciences (AREA)
Chemical Kinetics & Catalysis (AREA)
Microbiology (AREA)
Mycology (AREA)
Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
Peptides Or Proteins (AREA)
Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
Saccharide Compounds (AREA)
Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)
Treatments Of Macromolecular Shaped Articles (AREA)
Plural Heterocyclic Compounds (AREA)

ZA954570A 1994-06-03 1995-06-02 Conjugates of methyltrithio antitumor agents and intermediates for their synthesis ZA954570B (en)

Applications Claiming Priority (1)

Application Number	Priority Date	Filing Date	Title
US08/253,877 US5773001A (en)	1994-06-03	1994-06-03	Conjugates of methyltrithio antitumor agents and intermediates for their synthesis

Publications (1)

Publication Number	Publication Date
ZA954570B true ZA954570B (en)	1996-05-22

Family

ID=22962074

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
ZA954570A ZA954570B (en)	1994-06-03	1995-06-02	Conjugates of methyltrithio antitumor agents and intermediates for their synthesis

Country Status (20)

Country	Link
US (4)	US5773001A (de)
EP (1)	EP0689845B1 (de)
JP (2)	JP3650165B2 (de)
KR (1)	KR100408376B1 (de)
AT (1)	ATE223234T1 (de)
AU (1)	AU697280B2 (de)
BR (2)	BR1100990A (de)
CA (1)	CA2150785C (de)
CY (1)	CY2334B1 (de)
DE (1)	DE69528016T2 (de)
DK (1)	DK0689845T3 (de)
ES (1)	ES2181752T3 (de)
FI (1)	FI117690B (de)
IL (1)	IL113984A (de)
NO (1)	NO313617B1 (de)
NZ (3)	NZ536440A (de)
PT (1)	PT689845E (de)
SI (1)	SI0689845T1 (de)
TW (1)	TW394778B (de)
ZA (1)	ZA954570B (de)

Families Citing this family (770)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US5773001A (en) *	1994-06-03	1998-06-30	American Cyanamid Company	Conjugates of methyltrithio antitumor agents and intermediates for their synthesis
US5714586A (en) *	1995-06-07	1998-02-03	American Cyanamid Company	Methods for the preparation of monomeric calicheamicin derivative/carrier conjugates
US5712374A (en) *	1995-06-07	1998-01-27	American Cyanamid Company	Method for the preparation of substantiallly monomeric calicheamicin derivative/carrier conjugates
AU2335899A (en) *	1998-01-29	1999-08-16	Pharmacopeia, Inc.	Acid cleavable phenoxyalkyl linker for combinatorial synthesis
US6008321A (en) *	1998-03-16	1999-12-28	Pharmacopeia, Inc.	Universal linker for combinatorial synthesis
US6914130B2 (en) *	1998-06-17	2005-07-05	Genentech, Inc.	Compositions and methods for the diagnosis and treatment of tumor
US6733998B1 (en)	1998-12-07	2004-05-11	Sloan-Kettering Institute For Cancer Research	Micromonospora echinospora genes coding for biosynthesis of calicheamicin and self-resistance thereto
US20050159588A1 (en) *	1999-06-02	2005-07-21	Genentech, Inc.	Compositions and methods for the diagnosis and treatment of tumor
CA2376596C (en)	1999-06-25	2009-10-06	Genentech, Inc.	Humanized anti-erbb2 antibodies and treatment with anti-erbb2 antibodies
EP2180054A1 (de) *	1999-12-24	2010-04-28	Genentech, Inc.	Verfahren und Zusammenstellungen zur Verlängerung der Entsorgungshalbzeiten von bioaktiven Verbindungen
US20060228364A1 (en) *	1999-12-24	2006-10-12	Genentech, Inc.	Serum albumin binding peptides for tumor targeting
US20050287153A1 (en) *	2002-06-28	2005-12-29	Genentech, Inc.	Serum albumin binding peptides for tumor targeting
US20040001827A1 (en) *	2002-06-28	2004-01-01	Dennis Mark S.	Serum albumin binding peptides for tumor targeting
EP1261376A1 (de) *	2000-01-27	2002-12-04	Genetics Institute, LLC	Antikörper gegen ctla4(cd152), sie enthaltende konjugate und ihre verwendung
CN101289511A (zh)	2000-04-11	2008-10-22	杰南技术公司	多价抗体及其应用
ES2359625T3 (es)	2000-12-28	2011-05-25	Wyeth Llc	Proteina protectora recombinante de.
US6652853B2 (en) *	2001-03-08	2003-11-25	Ludwig Institute For Cancer Research	Method for treating cancer using A33 specific antibodies and chemotherapeutic agents
NZ511705A (en) *	2001-05-14	2004-03-26	Horticulture & Food Res Inst	Methods and rapid immunoassay device for detecting progesterone and other steroids
US7129261B2 (en)	2001-05-31	2006-10-31	Medarex, Inc.	Cytotoxic agents
US20070160576A1 (en)	2001-06-05	2007-07-12	Genentech, Inc.	IL-17A/F heterologous polypeptides and therapeutic uses thereof
CA2633171C (en)	2001-06-20	2012-11-20	Genentech, Inc.	Antibodies against tumor-associated antigenic target (tat) polypeptides
US7803915B2 (en)	2001-06-20	2010-09-28	Genentech, Inc.	Antibody compositions for the diagnosis and treatment of tumor
US20050107595A1 (en) *	2001-06-20	2005-05-19	Genentech, Inc.	Compositions and methods for the diagnosis and treatment of tumor
US20040086504A1 (en) *	2001-06-21	2004-05-06	Deepak Sampath	Cyr61 as a target for treatment and diagnosis of breast cancer
US20040235068A1 (en) *	2001-09-05	2004-11-25	Levinson Arthur D.	Methods for the identification of polypeptide antigens associated with disorders involving aberrant cell proliferation and compositions useful for the treatment of such disorders
EP1487877B1 (de)	2001-09-18	2010-10-27	Genentech, Inc.	Zusammensetzungen und verfahren für die diagnose von tumoren
US20040023910A1 (en) *	2001-09-28	2004-02-05	Zhiming Zhang	Use of cyr61 in the treatment and diagnosis of human uterine leiomyomas
WO2003088808A2 (en)	2002-04-16	2003-10-30	Genentech, Inc.	Compositions and methods for the diagnosis and treatment of tumor
US20110045005A1 (en) *	2001-10-19	2011-02-24	Craig Crowley	Compositions and methods for the treatment of tumor of hematopoietic origin
NZ533933A (en)	2002-01-02	2008-06-30	Genentech Inc	Compositions and methods for the diagnosis and treatment of glioma tumor
US20040132101A1 (en)	2002-09-27	2004-07-08	Xencor	Optimized Fc variants and methods for their generation
US20100311954A1 (en) *	2002-03-01	2010-12-09	Xencor, Inc.	Optimized Proteins that Target Ep-CAM
US7662925B2 (en) *	2002-03-01	2010-02-16	Xencor, Inc.	Optimized Fc variants and methods for their generation
US20090042291A1 (en) *	2002-03-01	2009-02-12	Xencor, Inc.	Optimized Fc variants
SI2371392T1 (sl)	2002-05-02	2015-10-30	Wyeth Holdings Llc	Konjugati derivat-nosilec kaliheamicina
ES2392525T3 (es)	2002-07-15	2012-12-11	F. Hoffmann-La Roche Ag	Tratamiento del cáncer con el anticuerpo dirigido contra ErbB2 rhuMAb 2C4
WO2004029207A2 (en)	2002-09-27	2004-04-08	Xencor Inc.	Optimized fc variants and methods for their generation
SI2301965T1 (sl)	2002-10-16	2015-07-31	Purdue Pharma L.P.	Protitelesa, ki vežejo celično- povezan CA 125 / O722P in metode uporabe le-teh
US20040152632A1 (en) *	2002-11-06	2004-08-05	Wyeth	Combination therapy for the treatment of acute leukemia and myelodysplastic syndrome
US20090010920A1 (en) *	2003-03-03	2009-01-08	Xencor, Inc.	Fc Variants Having Decreased Affinity for FcyRIIb
US8388955B2 (en)	2003-03-03	2013-03-05	Xencor, Inc.	Fc variants
PL2784084T5 (pl)	2003-07-08	2024-12-02	Novartis Pharma Ag	Przeciwciała antagonistyczne heterologicznych polipeptydów il-17a/f
PL2256106T3 (pl)	2003-07-22	2015-08-31	Astex Therapeutics Ltd	Związki 3,4-pochodne 1h-pirazolu i ich zastosowanie jako kinazy zależne od cyklin (cdk) i modulatory kinazy syntazy glikogenu-3 (gsk-3)
CA2533878A1 (en) *	2003-07-29	2005-09-22	Immunomedics, Inc.	Fluorinated carbohydrate conjugates
CA2534055A1 (en) *	2003-08-01	2005-02-10	Genentech, Inc.	Antibody cdr polypeptide sequences with restricted diversity
US8101720B2 (en) *	2004-10-21	2012-01-24	Xencor, Inc.	Immunoglobulin insertions, deletions and substitutions
US9714282B2 (en)	2003-09-26	2017-07-25	Xencor, Inc.	Optimized Fc variants and methods for their generation
US20050282168A1 (en) *	2003-09-29	2005-12-22	Wyeth	Cell surface molecules as markers and therapeutic agents against kidney cancers
US7498298B2 (en)	2003-11-06	2009-03-03	Seattle Genetics, Inc.	Monomethylvaline compounds capable of conjugation to ligands
SI2295073T1 (sl)	2003-11-17	2014-07-31	Genentech, Inc.	Protitelo proti CD22 za zdravljenje tumorja hematopoetskega izvora
KR100956913B1 (ko)	2003-12-19	2010-05-11	제넨테크, 인크.	치료제로서 유용한 일가 항체 단편
AR048098A1 (es) *	2004-03-15	2006-03-29	Wyeth Corp	Conjugados de caliqueamicina
CN1961003B (zh)	2004-03-31	2013-03-27	健泰科生物技术公司	人源化抗TGF-β抗体
WO2005101017A1 (en) *	2004-04-07	2005-10-27	Genentech, Inc.	Mass spectrometry of antibody conjugates
RU2402548C2 (ru) *	2004-05-19	2010-10-27	Медарекс, Инк.	Химические линкеры и их конъюгаты
JP4806680B2 (ja) *	2004-05-19	2011-11-02	メダレックスインコーポレイテッド	自己犠牲リンカー及び薬剤複合体
KR20120064120A (ko)	2004-06-01	2012-06-18	제넨테크, 인크.	항체 약물 접합체 및 방법
CN103172731A (zh)	2004-07-15	2013-06-26	赞科股份有限公司	优化的Fc变体
WO2006014729A2 (en)	2004-07-20	2006-02-09	Genentech, Inc.	Inhibitors of angiopoietin-like 4 protein, combinations, and their use
AU2005269463B2 (en)	2004-07-26	2011-08-18	Genentech, Inc.	Methods and compositions for modulating hepatocyte growth factor activation
CA2486285C (en) *	2004-08-30	2017-03-07	Viktor S. Goldmakher	Immunoconjugates targeting syndecan-1 expressing cells and use thereof
RS52213B (sr) *	2004-09-03	2012-10-31	Genentech, Inc.	Humanizovani anti-beta7 antagonisti i njihove primene
PE20100251A1 (es) *	2004-09-10	2010-04-10	Wyeth Corp	Anticuerpos anti-5t4 humanizados y conjugados anticuerpo anti-5t4/calicheamicina
KR101270829B1 (ko)	2004-09-23	2013-06-07	제넨테크, 인크.	시스테인 유전자조작 항체 및 접합체
JP2008515889A (ja) *	2004-10-05	2008-05-15	ジェネンテック・インコーポレーテッド	毒性の低下した治療剤
JO3000B1 (ar)	2004-10-20	2016-09-05	Genentech Inc	مركبات أجسام مضادة .
DK1817340T3 (da)	2004-11-12	2012-08-13	Xencor Inc	Fc-varianter med ændret binding til fcrn
US8367805B2 (en)	2004-11-12	2013-02-05	Xencor, Inc.	Fc variants with altered binding to FcRn
US20070135620A1 (en) *	2004-11-12	2007-06-14	Xencor, Inc.	Fc variants with altered binding to FcRn
US8802820B2 (en) *	2004-11-12	2014-08-12	Xencor, Inc.	Fc variants with altered binding to FcRn
US8546543B2 (en)	2004-11-12	2013-10-01	Xencor, Inc.	Fc variants that extend antibody half-life
EP1817059A2 (de)	2004-12-01	2007-08-15	Genentech, Inc.	Konjugate von 1,8-bis-naphthalimiden mit einem antikörper
EP1841793B1 (de)	2005-01-07	2010-03-31	Diadexus, Inc.	Ovr110-antikörperzusammensetzungen und verwendungsverfahren dafür
CA2592177A1 (en)	2005-01-21	2006-07-27	Genentech, Inc.	Fixed dosing of her antibodies
US8404718B2 (en)	2005-01-21	2013-03-26	Astex Therapeutics Limited	Combinations of pyrazole kinase inhibitors
AR054425A1 (es)	2005-01-21	2007-06-27	Astex Therapeutics Ltd	Sales de adicion de piperidin 4-il- amida de acido 4-(2,6-dicloro-benzoilamino) 1h-pirazol-3-carboxilico.
RU2436575C2 (ru) *	2005-01-21	2011-12-20	Астекс Терапьютикс Лимитед	Соединения для использования в фармацевтике
MX2007008781A (es)	2005-01-21	2007-09-11	Astex Therapeutics Ltd	Compuestos farmaceuticos.
NZ556661A (en) *	2005-02-18	2010-10-29	Medarex Inc	Human monoclonal antibodies to prostate specific membrance antigen (PSMA)
EP1850874B1 (de)	2005-02-23	2013-10-16	Genentech, Inc.	Verzögerung des krankheitsverlauf bei eierstockkrebspatienten durch pertuzumab
WO2006096861A2 (en) *	2005-03-08	2006-09-14	Genentech, Inc.	METHODS FOR IDENTIFYING TUMORS RESPONSIVE TO TREATMENT WITH HER DIMERIZATION INHIBITORS (HDIs)
AU2006235276A1 (en)	2005-04-07	2006-10-19	Novartis Vaccines And Diagnostics Inc.	CACNA1E in cancer diagnosis, detection and treatment
EP1871911A2 (de)	2005-04-07	2008-01-02	Chiron Corporation	Gene in verbindung mit krebs (prlr)
US7714016B2 (en) *	2005-04-08	2010-05-11	Medarex, Inc.	Cytotoxic compounds and conjugates with cleavable substrates
CA2610709A1 (en)	2005-06-06	2006-12-14	Genentech, Inc.	Transgenic models for different genes and their use for gene characterization
US20070003559A1 (en) *	2005-07-01	2007-01-04	Wyeth	Methods of determining pharmacokinetics of targeted therapies
WO2007008943A2 (en)	2005-07-08	2007-01-18	Xencor, Inc.	Optimized anti-ep-cam antibodies
US7931902B2 (en)	2005-08-15	2011-04-26	Genentech, Inc.	Gene disruptions, compositions and methods relating thereto
CA2624662A1 (en)	2005-09-30	2007-04-12	The Government Of The United States Of America, As Represented By The Se Cretary Of Health And Human Services	Methods and compositions for modulating immune tolerance
WO2007041635A2 (en)	2005-10-03	2007-04-12	Xencor, Inc.	Fc variants with optimized fc receptor binding properties
SI1940789T1 (sl)	2005-10-26	2012-03-30	Medarex Inc	Postopki in spojine za pripravo cc analogov
EP1957531B1 (de)	2005-11-07	2016-04-13	Genentech, Inc.	Bindungspolypeptide mit diversifizierten und konsensus-vh/vl-hypervariablen sequenzen
CA2627190A1 (en)	2005-11-10	2007-05-24	Medarex, Inc.	Duocarmycin derivatives as novel cytotoxic compounds and conjugates
WO2007081608A2 (en)	2005-11-21	2007-07-19	Genentech, Inc.	Novel gene disruptions, compositions and methods relating thereto
WO2007064919A2 (en) *	2005-12-02	2007-06-07	Genentech, Inc.	Binding polypeptides with restricted diversity sequences
EP1954719A2 (de)	2005-12-02	2008-08-13	Genentech Inc.	Zusammensetzungen und verfahren zur behandlung von krankheiten und leiden in zusammenhang mit zytokin-signalisierung sowie unter verwendung an il-22 und il-22r bindender antikörper
AU2006338198B2 (en) *	2005-12-02	2012-04-26	Genentech, Inc.	Binding polypeptides and uses thereof
BRPI0619476A2 (pt) *	2005-12-05	2011-10-04	Wyeth Corp	composições de interleucina-11 e métodos de uso
CA2633887C (en)	2005-12-15	2015-12-22	Genentech, Inc.	Methods and compositions for targeting polyubiquitin
AU2007248444B2 (en)	2006-01-05	2012-10-25	Genentech, Inc.	Anti-EphB4 antibodies and methods using same
US20080311107A1 (en)	2006-02-17	2008-12-18	Genetech, Inc.	Novel Gene Disruptions, Compositions and Methods Relating Thereto
AU2012261705B2 (en) *	2006-02-21	2014-02-06	Wyeth Llc	Processes for the convergent synthesis of calicheamicin derivatives
AU2014202414B2 (en) *	2006-02-21	2016-06-02	Wyeth Llc	Processes for the convergent synthesis of calicheamicin derivatives
TW200806685A (en)	2006-02-21	2008-02-01	Wyeth Corp	Processes for the convergent synthesis of calicheamicin derivatives
EP2946786A1 (de)	2006-03-08	2015-11-25	Wake Forest University Health Sciences	Lösliches monomeres Ephrin-A1
MY148763A (en)	2006-03-10	2013-05-31	Wyeth Corp	Anti-5t4 antibodies and uses thereof
AR059851A1 (es)	2006-03-16	2008-04-30	Genentech Inc	Anticuerpos de la egfl7 y metodos de uso
EP2389947A1 (de)	2006-03-23	2011-11-30	Novartis AG	Antitumorzellenantigen-Antikörper-Therapeutika
WO2007126455A2 (en)	2006-04-05	2007-11-08	Genentech, Inc.	Method for using boc/cdo to modulate hedgehog signaling
CN101622273A (zh)	2006-04-13	2010-01-06	诺瓦提斯疫苗和诊断公司	治疗、诊断或检测与liv-1过量表达相关的癌症的方法
EP2082645A1 (de)	2006-04-19	2009-07-29	Genentech, Inc.	Neuartige Genunterbrechungen, dazugehörige Zusammensetzungen und Verfahren in Zusammenhang damit
US20090142259A1 (en) *	2006-05-12	2009-06-04	Genentech, Inc.	Compositions and methods for the diagnosis and treatment of bladder and urinary tract tumors
ES2567402T3 (es)	2006-05-30	2016-04-22	Genentech, Inc.	Anticuerpos anti CD22, sus inmunoconjugados y usos de los mismos
PL2383297T3 (pl)	2006-08-14	2013-06-28	Xencor Inc	Zoptymalizowane przeciwciała ukierunkowane na CD19
US20100008910A1 (en)	2006-09-12	2010-01-14	John Chant	Methods and compositions for the diagnosis and treatment of cancer
JP5528807B2 (ja)	2006-10-12	2014-06-25	アステックス、セラピューティックス、リミテッド	複合薬剤
WO2008044041A1 (en)	2006-10-12	2008-04-17	Astex Therapeutics Limited	Pharmaceutical combinations
KR20140116546A (ko)	2006-10-27	2014-10-02	제넨테크, 인크.	항체 및 면역접합체 및 이들의 용도
US8444971B2 (en)	2006-11-27	2013-05-21	Diadexus, Inc.	OVR110 antibody compositions and methods of use
TWI412367B (zh)	2006-12-28	2013-10-21	梅達雷克斯有限責任公司	化學鏈接劑與可裂解基質以及其之綴合物
AR065271A1 (es)	2007-02-09	2009-05-27	Genentech Inc	Anticuerpos anti-robo4 y sus usos
CA2678514A1 (en)	2007-02-21	2008-08-28	Medarex, Inc.	Chemical linkers with single amino acids and conjugates thereof
MX2009008981A (es)	2007-03-02	2009-09-02	Genentech Inc	Prediccion de respuesta a un inhibidor her.
US8846005B2 (en)	2007-03-14	2014-09-30	Novartis Ag	APCDD1 inhibitors for treating, diagnosing or detecting cancer
US7960139B2 (en)	2007-03-23	2011-06-14	Academia Sinica	Alkynyl sugar analogs for the labeling and visualization of glycoconjugates in cells
EP2155248B1 (de)	2007-04-12	2015-06-10	The Brigham and Women's Hospital, Inc.	Abcb5-targeting zur krebstherapie
CA2693053C (en)	2007-05-30	2021-01-05	Xencor, Inc.	Methods and compositions for inhibiting cd32b expressing cells
PE20090321A1 (es)	2007-06-04	2009-04-20	Genentech Inc	Anticuerpos anti-notch1 nrr, metodo de preparacion y composicion farmaceutica
NZ583318A (en)	2007-07-16	2012-07-27	Genentech Inc	Humanized anti-cd79b antibodies and immunoconjugates and methods of use
DK2474557T3 (da)	2007-07-16	2014-11-10	Genentech Inc	Anti-CD79b-antistoffer og immunkonjugater og fremgangsmåder til anvendelse
AU2008304748C1 (en)	2007-09-26	2014-06-12	Chugai Seiyaku Kabushiki Kaisha	Modified antibody constant region
JP5695905B2 (ja)	2007-10-02	2015-04-08	ジェネンテック，インコーポレイテッド	Ｎｌｒｒ−１アンタゴニスト及びその使用
US20110033476A1 (en) *	2007-11-12	2011-02-10	Theraclone Sciences Inc.	Compositions and methods for the therapy and diagnosis of influenza
NZ585500A (en)	2007-11-12	2012-06-29	Theraclone Sciences Inc	Antibodies which bind to an epitope in the extracellular domain of the matrix 2 ectodomain polypeptide of an influenza virus
TWI580694B (zh)	2007-11-30	2017-05-01	建南德克公司	抗-ｖｅｇｆ抗體
RU2529951C2 (ru)	2007-12-26	2014-10-10	Ксенкор, Инк.	ВАРИАНТЫ Fc С ИЗМЕНЕННЫМ СВЯЗЫВАНИЕМ C FcRn
JP2011507933A (ja) *	2007-12-26	2011-03-10	バイオテスト・アクチエンゲゼルシヤフト	免疫複合体の細胞傷害性副作用の低減及び有効性の改善方法
EP2240516B1 (de) *	2007-12-26	2015-07-08	Biotest AG	Verfahren und mittel zur verbesserten abzielung auf cd138-exprimierende tumorzellen
CA2710453C (en)	2007-12-26	2019-07-02	Biotest Ag	Agents targeting cd138 and uses thereof
ES2526433T3 (es) *	2007-12-26	2015-01-12	Biotest Ag	Inmunoconjugados dirigidos a CD138 y usos de los mismos
JP2011509675A (ja)	2008-01-18	2011-03-31	メディミューン，エルエルシー	部位特異的コンジュゲーションのためのシステイン操作抗体
TWI472339B (zh)	2008-01-30	2015-02-11	Genentech Inc	包含結合至ｈｅｒ２結構域ii之抗體及其酸性變異體的組合物
SG187517A1 (en)	2008-01-31	2013-02-28	Genentech Inc	Anti-cd79b antibodies and immunoconjugates and methods of use
US12492253B1 (en)	2008-02-25	2025-12-09	Xencor, Inc.	Anti-human C5 antibodies
AU2009223688B2 (en)	2008-03-10	2014-12-11	Theraclone Sciences, Inc.	Compositions and methods for the therapy and diagnosis of cytomegalovirus infections
EP2631302A3 (de) *	2008-03-31	2014-01-08	Genentech, Inc.	Zusammensetzungen und Verfahren zur Behandlung und Diagnose von Asthma
EP3208612B1 (de)	2008-04-09	2019-09-18	Genentech, Inc.	Zusammensetzungen und verfahren zur behandlung von immunbedingten erkrankungen
DK2279004T3 (en) *	2008-05-16	2015-02-02	Hoffmann La Roche	USE OF biomarkers for assessment of treatment of gastrointestinal inflammatory disorders WITH beta7 integrin antagonists
JP5986745B2 (ja)	2008-07-15	2016-09-06	アカデミアシニカＡｃａｄｅｍｉａＳｉｎｉｃａ	Ｐｔｆｅ様のアルミニウム・コート・ガラススライド上のグリカンアレイおよび関連する方法
EP2633864A1 (de)	2008-07-25	2013-09-04	The Regents of the University of Colorado	Clip-Hemmer und Verfahren zur Modulation der Immunfunktion
PE20120080A1 (es)	2008-10-01	2012-02-17	Genentech Inc	Anticuerpos anti-notch2 y metodos de uso
MX2011006516A (es)	2008-12-17	2011-08-04	Genentech Inc	Terapia de combinacion de virus de hepatitis c.
KR101722961B1 (ko)	2009-02-11	2017-04-04	알부메딕스 에이/에스	알부민 변이체 및 접합체
SI3260136T1 (sl)	2009-03-17	2021-05-31	Theraclone Sciences, Inc.	Humani imunodeficientni virus (HIV)-nevtralizirajoča protitelesa
CN104447995A (zh)	2009-03-20	2015-03-25	霍夫曼-拉罗奇有限公司	双特异性抗-her抗体
MY173526A (en)	2009-03-25	2020-01-31	Genentech Inc	Novel anti-?5?1 antibodies and uses thereof
TWI507205B (zh)	2009-03-25	2015-11-11	Genentech Inc	抗ｆｇｆｒ３抗體及使用方法
WO2010120561A1 (en)	2009-04-01	2010-10-21	Genentech, Inc.	Anti-fcrh5 antibodies and immunoconjugates and methods of use
PE20120591A1 (es)	2009-04-02	2012-05-23	Roche Glycart Ag	Anticuerpos multiespecificos que comprenden anticuerpos de longitud completa y fragmentos fab de cadena sencilla
US8722860B2 (en)	2009-04-16	2014-05-13	Abbvie Biotherapeutics Inc.	Anti-TNF-α antibodies and their uses
US9296785B2 (en)	2009-04-17	2016-03-29	Wake Forest University Health Sciences	IL-13 receptor binding peptides
CN102459340A (zh) *	2009-04-23	2012-05-16	特罗科隆科学有限公司	粒性白血细胞-巨噬细胞菌落-刺激因子(gm-csf)中和抗体
JP2012527473A (ja)	2009-05-20	2012-11-08	セラクローンサイエンシーズ，インコーポレイテッド	インフルエンザの治療および診断のための組成物および方法
CA2763935A1 (en)	2009-06-04	2010-12-09	Novartis Ag	Methods for identification of sites for igg conjugation
PE20120622A1 (es)	2009-06-17	2012-05-26	Abbott Biotherapeutics Corp	Anticuerpos anti-vegf y sus usos
AU2010270979B2 (en)	2009-06-22	2015-04-23	Medimmune, Llc	Engineered Fc regions for site-specific conjugation
RU2567803C2 (ru)	2009-07-31	2015-11-10	Дженентек, Инк.	ИНГИБИРОВАНИЕ МЕТАСТАЗИРОВАНИЯ ОПУХОЛИ ПРИ ПОМОЩИ АНТАГОНИСТОВ Bv8 ИЛИ G-CSF
DK2473522T3 (en)	2009-09-02	2016-11-28	Genentech Inc	Smoothened MUTANT AND METHODS OF USING THE SAME
US9493578B2 (en)	2009-09-02	2016-11-15	Xencor, Inc.	Compositions and methods for simultaneous bivalent and monovalent co-engagement of antigens
KR20120108967A (ko)	2009-09-16	2012-10-05	제넨테크, 인크.	코일드 코일 및/또는 테더 함유 단백질 복합체 및 그의 용도
EP2486023A4 (de)	2009-10-06	2014-05-07	Immunogen Inc	Wirkungsstarke konjugate und hydrophile binder
HUE026447T2 (en)	2009-10-16	2016-05-30	Novartis Ag	Pharmacodynamic tumor response biomarkers
US8759491B2 (en) *	2009-10-19	2014-06-24	Genentech, Inc.	Modulators of hepatocyte growth factor activator
US8697386B2 (en)	2009-10-22	2014-04-15	Genentech, Inc.	Methods and compositions for modulating hepsin activation of macrophage-stimulating protein
EP2491059B1 (de)	2009-10-22	2015-02-25	F.Hoffmann-La Roche Ag	Anti-hepsin-antikörper sowie verfahren zu ihrer verwendung
WO2011056502A1 (en)	2009-10-26	2011-05-12	Genentech, Inc.	Bone morphogenetic protein receptor type ii compositions and methods of use
WO2011056494A1 (en)	2009-10-26	2011-05-12	Genentech, Inc.	Activin receptor-like kinase-1 antagonist and vegfr3 antagonist combinations
WO2011056497A1 (en)	2009-10-26	2011-05-12	Genentech, Inc.	Activin receptor type iib compositions and methods of use
TW201122101A (en)	2009-10-28	2011-07-01	Facet Biotech Corp	Anti-EGFR antibodies and their uses
CA2776241A1 (en)	2009-10-30	2011-05-05	Novozymes Biopharma Dk A/S	Albumin variants
BR112012010153B1 (pt)	2009-11-05	2022-05-03	Genentech, Inc	Método de produção de um anticorpo
BR112012012750A2 (pt)	2009-11-30	2020-08-11	Genentech Inc	anticorpo isolado, célula, ácido nucleíco isolado e método
US11377485B2 (en)	2009-12-02	2022-07-05	Academia Sinica	Methods for modifying human antibodies by glycan engineering
US10087236B2 (en)	2009-12-02	2018-10-02	Academia Sinica	Methods for modifying human antibodies by glycan engineering
EP2507381A4 (de)	2009-12-04	2016-07-20	Hoffmann La Roche	Multispezifische antikörper, antikörperanaloge, zusammensetzungen und verfahren
PH12012500881A1 (en)	2009-12-10	2017-07-26	Hoffmann La Roche	Antibodies binding preferentially human csf1r extracellular domain 4 and their use
JP5818805B2 (ja)	2009-12-11	2015-11-18	ジェネンテック，インコーポレイテッド	抗ｖｅｇｆ−ｃ抗体及びその使用方法
ES2594893T3 (es)	2009-12-16	2016-12-23	Abbvie Biotherapeutics Inc.	Anticuerpos anti HER2 y sus usos
HRP20160422T1 (hr)	2009-12-23	2016-05-20	Synimmune Gmbh	Protutijela protiv flt3 postupci njihove upotrebe
RU2559542C2 (ru)	2009-12-23	2015-08-10	Дженентек, Инк.	Антитела против bv8 и их применение
WO2011089211A1 (en)	2010-01-22	2011-07-28	Synimmune Gmbh	Anti-cd133 antibodies and methods of using the same
JP5858932B2 (ja)	2010-02-04	2016-02-10	モルフォテック，インコーポレイテッド	クロロトキシンポリペプチドおよびコンジュゲートならびにその使用
AU2011213609B2 (en)	2010-02-08	2016-11-03	Agensys, Inc.	Antibody drug conjugates (ADC) that bind to 161P2F10B proteins
DK2536748T3 (da)	2010-02-18	2014-10-13	Genentech Inc	Neuregulin-antagonister og anvendelse deraf ved behandling af kræft
TWI429453B (zh)	2010-02-23	2014-03-11	建南德克公司	抗tat419抗體及其用途
CA2789076C (en)	2010-03-05	2017-11-21	F. Hoffmann-La Roche Ag	Antibodies against human colony stimulating factor-1 receptor and uses thereof
CN102918061B (zh)	2010-03-05	2016-06-08	霍夫曼-拉罗奇有限公司	针对人csf-1r的抗体及其用途
CN106432474A (zh)	2010-03-12	2017-02-22	艾伯维生物医疗股份有限公司	Ctla4蛋白和其用途
AR080795A1 (es)	2010-03-24	2012-05-09	Genentech Inc	Anticuerpos anti-lrp6 (proteina relacionada con el receptor ldl tipo 6)
TW201138821A (en)	2010-03-26	2011-11-16	Roche Glycart Ag	Bispecific antibodies
US10233228B2 (en)	2010-04-09	2019-03-19	Albumedix Ltd	Albumin derivatives and variants
US10338069B2 (en)	2010-04-12	2019-07-02	Academia Sinica	Glycan arrays for high throughput screening of viruses
CN102946906B (zh)	2010-04-23	2015-07-15	弗·哈夫曼-拉罗切有限公司	生产异源多聚体蛋白质
MX342239B (es)	2010-05-03	2016-09-21	Genentech Inc *	Composiciones y metodos para el diagnostico y tratamiento de tumores.
WO2011146568A1 (en)	2010-05-19	2011-11-24	Genentech, Inc.	Predicting response to a her inhibitor
RU2613886C2 (ru)	2010-06-03	2017-03-21	Дженентек, Инк.	Антитела и иммуноконъюгаты, визуализируемые при помощи иммуно-позитрон-эмиссионной томографии, и способы их применения
BR112012030311A2 (pt)	2010-06-08	2017-01-24	Genentech Inc	anticorpo
BR112012027995A2 (pt)	2010-06-18	2017-01-10	Genentech Inc	anticorpo e ácido nucleíco isolado, célula hospedeira, método de produção de um anticorpo, imunoconjugado, formulação farmacêutica, uso do anticorpo, método de tratamento de um indivíduo com câncer, de um indivíduo possuíndo um distúrbio imune, de inibição da angiogênese e para inibir a ativação constitutiva de axl
WO2011161119A1 (en)	2010-06-22	2011-12-29	F. Hoffmann-La Roche Ag	Antibodies against insulin-like growth factor i receptor and uses thereof
WO2011161189A1 (en)	2010-06-24	2011-12-29	F. Hoffmann-La Roche Ag	Anti-hepsin antibodies and methods of use
EP3029066B1 (de)	2010-07-29	2019-02-20	Xencor, Inc.	Antikörper mit modifizierten isoelektrischen punkten
JP2013541501A (ja)	2010-08-03	2013-11-14	エフ・ホフマン−ラ・ロシュ・アクチェンゲゼルシャフト	慢性リンパ性白血病（ｃｌｌ）のバイオマーカー
WO2012021786A2 (en)	2010-08-12	2012-02-16	Theraclone Sciences, Inc.	Anti-hemagglutinin antibody compositions and methods of use thereof
JP5841149B2 (ja)	2010-08-13	2016-01-13	ロシュグリクアートアーゲー	抗テネイシンｃａ２抗体及び使用の方法
HUE036077T2 (hu)	2010-08-13	2018-06-28	Roche Glycart Ag	Anti-FAP ellenanyagok és alkalmazásukra szolgáló eljárások
RU2013110844A (ru)	2010-08-13	2014-09-20	Дженентек, Инк.	АНТИТЕЛА ПРОТИВ IL-1β И IL-18, ИСПОЛЬЗУЕМЫЕ ДЛЯ ЛЕЧЕНИЯ ЗАБОЛЕВАНИЙ
WO2012025530A1 (en)	2010-08-24	2012-03-01	F. Hoffmann-La Roche Ag	Bispecific antibodies comprising a disulfide stabilized - fv fragment
KR20130103734A (ko)	2010-08-31	2013-09-24	제넨테크, 인크.	바이오마커 및 치료 방법
CA3249351A1 (en)	2010-08-31	2025-07-03	Theraclone Sciences, Inc.	Neutralizing antibodies against human immunodeficiency viruses (HIV)
JP5866130B2 (ja)	2010-09-10	2016-02-17	アペクシジェン，インコーポレイテッド	抗ＩＬ−１β抗体およびその使用方法
EP3409287B9 (de)	2010-09-29	2021-07-21	Agensys, Inc.	An 191p4d12-proteine bindende antikörper-wirkstoffkonjugate
EP3828205A1 (de)	2010-10-01	2021-06-02	Oxford BioTherapeutics Ltd	Anti-ror1-antikörper
UA112062C2 (uk) †	2010-10-04	2016-07-25	Бьорінгер Інгельхайм Інтернаціональ Гмбх	Cd33-зв'язувальний агент
US8481680B2 (en)	2010-10-05	2013-07-09	Genentech, Inc.	Mutant smoothened and methods of using the same
MX346500B (es)	2010-11-10	2017-03-22	Genentech Inc *	Metodos y composiciones para inmunoterapia para enfermedad neural.
EP2637692A4 (de)	2010-11-12	2014-09-10	Scott & White Healthcare	Antikörper gegen den endothelialen tumormarker 8
TWI732259B (zh)	2010-12-16	2021-07-01	美商建南德克公司	關於th2抑制作用之診斷及治療
PE20141114A1 (es)	2010-12-20	2014-09-15	Genentech Inc	Anticuerpos anti-mesotelina e inmunoconjugados
KR20130118925A (ko)	2010-12-22	2013-10-30	제넨테크, 인크.	항-pcsk9 항체 및 사용 방법
JP5766296B2 (ja)	2010-12-23	2015-08-19	エフ．ホフマン−ラロシュアーゲーＦ．Ｈｏｆｆｍａｎｎ−ＬａＲｏｃｈｅＡｋｔｉｅｎｇｅｓｅｌｌｓｃｈａｆｔ	ポリペプチド−ポリヌクレオチド複合体、およびエフェクター成分の標的化された送達におけるその使用
JOP20210044A1 (ar)	2010-12-30	2017-06-16	Takeda Pharmaceuticals Co	الأجسام المضادة لـ cd38
WO2012092539A2 (en)	2010-12-31	2012-07-05	Takeda Pharmaceutical Company Limited	Antibodies to dll4 and uses thereof
CN103649117B (zh)	2011-02-04	2016-09-14	霍夫曼-拉罗奇有限公司	Fc变体及其生成方法
US10689447B2 (en)	2011-02-04	2020-06-23	Genentech, Inc.	Fc variants and methods for their production
CA2827170A1 (en)	2011-02-11	2012-08-16	David M. Hilbert	Monovalent and multivalent multispecific complexes and uses thereof
JP2014506580A (ja)	2011-02-14	2014-03-17	セラクローンサイエンシーズ，インコーポレイテッド	インフルエンザの治療および診断のための組成物および方法
KR20140043724A (ko)	2011-03-03	2014-04-10	아펙시젠, 인코포레이티드	항-il-6 수용체 항체 및 사용 방법
CA2827759C (en)	2011-03-10	2018-10-16	Omeros Corporation	Generation of anti-fn14 monoclonal antibodies by ex-vivo accelerated antibody evolution
SG193402A1 (en)	2011-03-15	2013-10-30	Theraclone Sciences Inc	Compositions and methods for the therapy and diagnosis of influenza
JP6130307B2 (ja)	2011-03-17	2017-05-17	ザユニバーシティオブバーミンガム	再指向性免疫療法
SG10201602394QA (en)	2011-03-29	2016-05-30	Roche Glycart Ag	Antibody FC Variants
CA2828890A1 (en)	2011-04-07	2012-10-11	Genentech, Inc.	Anti-fgfr4 antibodies and methods of use
US20120282176A1 (en)	2011-04-20	2012-11-08	Roche Glycart Ag	Method and Constructs for the pH Dependent Passage of the Blood-brain-barrier
CN113461819B (zh)	2011-04-29	2024-01-02	埃派斯进有限公司	抗-cd40抗体及其使用方法
SI2710035T1 (sl)	2011-05-16	2017-07-31	F. Hoffmann-La Roche Ag	Agonisti FGFR1 in tehnike njihove uporabe
EP2714738B1 (de)	2011-05-24	2018-10-10	Zyngenia, Inc.	Multivalente und monovalente multispezifische komplexe und ihre verwendungen
CA2833820C (en)	2011-05-27	2019-10-29	Glaxo Group Limited	Bcma (cd269/tnfrsf17) -binding proteins
WO2012171020A1 (en)	2011-06-10	2012-12-13	Mersana Therapeutics, Inc.	Protein-polymer-drug conjugates
WO2013003507A1 (en)	2011-06-27	2013-01-03	Morphotek, Inc.	Multifunctional agents
RU2013155695A (ru)	2011-06-30	2015-08-10	Дженентек, Инк.	Препараты антител против с-мет
WO2013022855A1 (en)	2011-08-05	2013-02-14	Xencor, Inc.	Antibodies with modified isoelectric points and immunofiltering
EP2742067A4 (de)	2011-08-12	2015-03-04	Omeros Corp	Monoklonale fzd10-antikörper und verfahren zu ihrer verwendung
CA2842481A1 (en)	2011-08-17	2013-02-21	Genentech, Inc.	Inhibition of angiogenesis in refractory tumors
US20140363438A1 (en)	2011-08-17	2014-12-11	Genentech, Inc.	Neuregulin antibodies and uses thereof
WO2013026835A1 (en)	2011-08-23	2013-02-28	Roche Glycart Ag	Fc-free antibodies comprising two fab fragments and methods of use
BR112014004168A2 (pt)	2011-08-23	2017-12-12	Roche Glycart Ag	anticorpo biespecífico, composição farmacêutica, uso do anticorpo biespecífico, célula hospedeira procariótica ou eucariótica, método de produção de anticorpo e invenção
US8822651B2 (en)	2011-08-30	2014-09-02	Theraclone Sciences, Inc.	Human rhinovirus (HRV) antibodies
JP2014533927A (ja)	2011-09-15	2014-12-18	ジェネンテック，インコーポレイテッド	分化を促進する方法
AU2012312515A1 (en)	2011-09-19	2014-03-13	Genentech, Inc.	Combination treatments comprising c-met antagonists and B-raf antagonists
KR101684750B1 (ko)	2011-09-23	2016-12-08	로슈 글리카트 아게	이중특이적 항-egfr/항-igf-1r 항체
US20130089562A1 (en)	2011-10-05	2013-04-11	Genenthech, Inc.	Methods of treating liver conditions using notch2 antagonists
US12466897B2 (en)	2011-10-10	2025-11-11	Xencor, Inc.	Heterodimeric human IgG1 polypeptides with isoelectric point modifications
WO2013055809A1 (en)	2011-10-10	2013-04-18	Xencor, Inc.	A method for purifying antibodies
US10851178B2 (en)	2011-10-10	2020-12-01	Xencor, Inc.	Heterodimeric human IgG1 polypeptides with isoelectric point modifications
JP6134725B2 (ja)	2011-10-14	2017-05-24	ジェネンテック，インコーポレイテッド	Ｂａｃｅ１のペプチド阻害剤
CN103917556B (zh)	2011-10-14	2018-02-06	霍夫曼-拉罗奇有限公司	抗HtrA1抗体及使用方法
WO2013056148A2 (en)	2011-10-15	2013-04-18	Genentech, Inc.	Methods of using scd1 antagonists
JP6181059B2 (ja)	2011-10-25	2017-08-16	メモリアルスローン−ケタリングキャンサーセンター	前立腺がんのための診断薬、予後判定薬、および治療薬としてのフリーｐｓａ抗体
PE20142312A1 (es)	2011-10-28	2015-01-25	Genentech Inc	Combinaciones terapeuticas y metodos para tratar el melanoma
US9441042B2 (en)	2011-11-02	2016-09-13	Apexigen, Inc.	Anti-KDR antibodies and methods of use
EP2589609A1 (de)	2011-11-03	2013-05-08	Pierre Fabre Medicament	Antigenbindendes Protein und dessen Verwendung als Adressierungsprodukt bei der Behandlung von Krebs
EP2780364A2 (de)	2011-11-18	2014-09-24	Eleven Biotherapeutics, Inc.	Proteine mit verbesserter halbwertzeit und anderen eigenschaften
EP2782932A1 (de)	2011-11-21	2014-10-01	F.Hoffmann-La Roche Ag	Reinigung von anti-c-met-antikörpern
MX358680B (es)	2011-12-08	2018-08-31	Biotest Ag	Usos de inmunoconjugados dirigidos a cd138.
BR112014012624A2 (pt)	2011-12-15	2018-10-09	F Hoffmann-La Roche Ag	anticorpos, composição farmacêutica, ácido nucleico, vetores de expressão, célula hospedeira, método para a produção de um anticorpo recombinante e uso do anticorpo
US20130195851A1 (en)	2011-12-23	2013-08-01	Genentech, Inc.	Articles of manufacture and methods for co-administration of antibodies
US10774132B2 (en)	2012-01-09	2020-09-15	The Scripps Research Instittue	Ultralong complementarity determining regions and uses thereof
EP3663314A1 (de)	2012-01-09	2020-06-10	The Scripps Research Institute	Humanisierte antikörper mit ultralangem cdr3s
US20130183294A1 (en)	2012-01-18	2013-07-18	Genentech, Inc.	Methods of using fgf19 modulators
EP2804629A1 (de)	2012-01-18	2014-11-26	Genentech, Inc.	Anti-lrp5-antikörper und verwendungsverfahren
US9567642B2 (en)	2012-02-02	2017-02-14	Massachusetts Institute Of Technology	Methods and products related to targeted cancer therapy
WO2013119966A2 (en)	2012-02-10	2013-08-15	Genentech, Inc.	Single-chain antibodies and other heteromultimers
KR102148303B1 (ko)	2012-02-11	2020-08-26	제넨테크, 인크.	R-스폰딘 전위 및 그의 사용 방법
CA2860600C (en)	2012-02-15	2022-07-26	F. Hoffmann-La Roche Ag	Fc-receptor based affinity chromatography
GB201203442D0 (en)	2012-02-28	2012-04-11	Univ Birmingham	Immunotherapeutic molecules and uses
WO2013135896A1 (en)	2012-03-16	2013-09-19	Novozymes Biopharma Dk A/S	Albumin variants
WO2013148259A1 (en)	2012-03-28	2013-10-03	Massachusetts Institute Of Technology	Cancer-related extracellular matrix signatures and related methods and products
US10024860B2 (en)	2012-03-28	2018-07-17	Massachusetts Institute Of Technology	Cancer-related extracellular matrix signatures and related methods and products
AR090549A1 (es)	2012-03-30	2014-11-19	Genentech Inc	Anticuerpos anti-lgr5 e inmunoconjugados
US10130714B2 (en)	2012-04-14	2018-11-20	Academia Sinica	Enhanced anti-influenza agents conjugated with anti-inflammatory activity
AU2013256596A1 (en)	2012-05-01	2014-10-09	Genentech, Inc.	Anti-PMEL17 antibodies and immunoconjugates
WO2013170191A1 (en)	2012-05-11	2013-11-14	Genentech, Inc.	Methods of using antagonists of nad biosynthesis from nicotinamide
EP2861624A1 (de)	2012-06-15	2015-04-22	F. Hoffmann-La Roche AG	Anti-pcsk9-antikörper, formulierungen, dosierung und verfahren zur verwendung
WO2014001325A1 (en)	2012-06-27	2014-01-03	F. Hoffmann-La Roche Ag	Method for making antibody fc-region conjugates comprising at least one binding entity that specifically binds to a target and uses thereof
MX354862B (es)	2012-06-27	2018-03-23	Hoffmann La Roche	Método para la producción de entidades dirigidas altamente selectivas hechas a la medida y biespecíficas que contienen dos entidades de unión diferentes.
CA2871386A1 (en)	2012-06-27	2014-01-03	F. Hoffmann-La Roche Ag	Method for the selection and production of tailor-made, selective and multi-specific therapeutic molecules comprising at least two different targeting entities and uses thereof
ES2604012T3 (es)	2012-07-04	2017-03-02	F. Hoffmann-La Roche Ag	Conjugados de antígeno-anticuerpo unidos covalentemente
JP6247287B2 (ja)	2012-07-04	2017-12-13	エフ．ホフマン−ラロシュアーゲーＦ．Ｈｏｆｆｍａｎｎ−ＬａＲｏｃｈｅＡｋｔｉｅｎｇｅｓｅｌｌｓｃｈａｆｔ	抗ビオチン抗体および使用方法
EP3138578B1 (de)	2012-07-04	2022-01-12	F. Hoffmann-La Roche AG	Anti-theophyllin-antikörper und verfahren zur verwendung davon
LT3495387T (lt)	2012-07-13	2021-11-25	Roche Glycart Ag	Bispecifiniai anti-vegf / anti-ang-2 antikūnai ir jų panaudojimas akių kraujagyslių ligoms gydyti
WO2014031498A1 (en)	2012-08-18	2014-02-27	Academia Sinica	Cell-permeable probes for identification and imaging of sialidases
EP3494996B1 (de)	2012-08-23	2026-04-15	Agensys, Inc.	An 158p1d7-proteine bindende antikörperwirkstoffkonjugate
PL2897978T3 (pl)	2012-09-19	2017-08-31	Abbvie Biotherapeutics Inc.	Sposoby identyfikacji przeciwciał o obniżonej immunogenności
EP2904016B1 (de)	2012-10-08	2018-11-14	Roche Glycart AG	Fc-freie antikörper mit zwei fab-fragmenten sowie verwendungsverfahren dafür
DK2907824T3 (en)	2012-10-11	2018-07-23	Daiichi Sankyo Co Ltd	ANTIBODY-drug conjugate
EP2910573B1 (de)	2012-10-19	2020-02-19	Daiichi Sankyo Company, Limited	Durch bindung über einen linker mit hydrophiler struktur hergestelltes antikörper-wirkstoff-konjugat
AU2013334102B2 (en)	2012-10-26	2018-08-16	Memorial Sloan-Kettering Cancer Center	Modulators of resistant androgen receptor
AU2013337903B2 (en)	2012-10-30	2018-08-16	Apexigen, Inc.	Anti-CD40 antibodies and methods of use
JP6694712B2 (ja)	2012-11-01	2020-05-20	マックス−デルブルック−セントラムフアーモレキュラーレメデジン	Ｃｄ２６９（ｂｃｍａ）に対する抗体
PL2914630T3 (pl)	2012-11-05	2021-09-06	Pierre Fabre Médicament	Nowe białka wiążące antygen i ich zastosowanie jako produktu ukierunkowanego do leczenia raka
MX2015005757A (es)	2012-11-08	2015-11-18	Hoffmann La Roche	Proteinas ligantes de antigeno her3 de union a la horquilla beta de her3.
MX2015005363A (es)	2012-11-08	2015-11-06	Novozymes Biopharma Dk As	Variantes de albumina.
SG10201700488QA (en)	2012-11-13	2017-02-27	Genentech Inc	Anti-hemagglutinin antibodies and methods of use
US10131682B2 (en)	2012-11-24	2018-11-20	Hangzhou Dac Biotech Co., Ltd.	Hydrophilic linkers and their uses for conjugation of drugs to a cell binding molecules
US20140154255A1 (en)	2012-11-30	2014-06-05	Abbvie Biotherapeutics Inc.	Anti-vegf antibodies and their uses
CA2892863C (en)	2012-12-10	2022-03-15	Mersana Therapeutics, Inc.	Polymeric scaffold based on phf for targeted drug delivery
WO2014093640A1 (en)	2012-12-12	2014-06-19	Mersana Therapeutics,Inc.	Hydroxy-polmer-drug-protein conjugates
WO2014107739A1 (en)	2013-01-07	2014-07-10	Eleven Biotherapeutics, Inc.	Antibodies against pcsk9
US10487155B2 (en)	2013-01-14	2019-11-26	Xencor, Inc.	Heterodimeric proteins
US11053316B2 (en)	2013-01-14	2021-07-06	Xencor, Inc.	Optimized antibody variable regions
US9605084B2 (en)	2013-03-15	2017-03-28	Xencor, Inc.	Heterodimeric proteins
CA2898100C (en)	2013-01-14	2023-10-10	Xencor, Inc.	Novel heterodimeric proteins
US10131710B2 (en)	2013-01-14	2018-11-20	Xencor, Inc.	Optimized antibody variable regions
US10968276B2 (en)	2013-03-12	2021-04-06	Xencor, Inc.	Optimized anti-CD3 variable regions
US9701759B2 (en)	2013-01-14	2017-07-11	Xencor, Inc.	Heterodimeric proteins
US9738722B2 (en)	2013-01-15	2017-08-22	Xencor, Inc.	Rapid clearance of antigen complexes using novel antibodies
EP2958592A1 (de)	2013-02-22	2015-12-30	F. Hoffmann-La Roche AG	Verfahren zur behandlung von krebs und zur verhinderung von arzneimittelresistenz
RU2015140921A (ru)	2013-02-26	2017-04-03	Роше Гликарт Аг	Антитела к mcsp
KR20150123250A (ko)	2013-03-06	2015-11-03	제넨테크, 인크.	암 약물 내성의 치료 및 예방 방법
AU2014244424A1 (en)	2013-03-14	2015-08-27	Genentech, Inc.	Anti-B7-H4 antibodies and immunoconjugates
KR20150127216A (ko)	2013-03-14	2015-11-16	제넨테크, 인크.	암의 치료 및 암 약물 내성의 예방 방법
US9562099B2 (en)	2013-03-14	2017-02-07	Genentech, Inc.	Anti-B7-H4 antibodies and immunoconjugates
BR112015023752B1 (pt)	2013-03-15	2023-11-14	Zyngenia, Inc.	Domínio de reconhecimento modular (mrd), complexo compreendendo mrd e cetuximabe, usos do complexo para inibir a angiogênese e tratar câncer e composição farmacêutica compreendendo o dito complexo
EP2970471A2 (de)	2013-03-15	2016-01-20	F. Hoffmann-La Roche AG	Anti-crth2-antikörper und deren verwendung
KR102389677B1 (ko)	2013-03-15	2022-04-21	제넨테크, 인크.	Pd-1 및 pd-l1 관련 상태를 치료하기 위한 바이오마커 및 방법
MX2015012563A (es)	2013-03-15	2016-10-26	Abbvie Biotechnology Ltd	Anticuerpos anti-cd25 y sus usos.
CN105143258B (zh)	2013-03-15	2020-06-23	Ac免疫有限公司	抗Tau抗体和使用方法
US10519242B2 (en)	2013-03-15	2019-12-31	Xencor, Inc.	Targeting regulatory T cells with heterodimeric proteins
EP2970486B1 (de)	2013-03-15	2018-05-16	Xencor, Inc.	Modulation von t-zellen mit bispezifischen antikörpern und fc-fusionen
ES2699599T3 (es)	2013-03-15	2019-02-11	Abbvie Biotherapeutics Inc	Variantes de Fc
CA2902739C (en)	2013-03-15	2022-11-22	Xencor, Inc.	Heterodimeric proteins
EP2970488A2 (de)	2013-03-15	2016-01-20	AbbVie Biotechnology Ltd	Anti-cd25-antikörper und deren verwendungen
US10858417B2 (en)	2013-03-15	2020-12-08	Xencor, Inc.	Heterodimeric proteins
SG10201706210WA (en)	2013-03-15	2017-09-28	Genentech Inc	Compositions and methods for diagnosis and treatment of hepatic cancers
US10106624B2 (en)	2013-03-15	2018-10-23	Xencor, Inc.	Heterodimeric proteins
WO2014144850A1 (en)	2013-03-15	2014-09-18	Genentech, Inc.	Methods of treating cancer and preventing cancer drug resistance
AR095882A1 (es)	2013-04-22	2015-11-18	Hoffmann La Roche	Terapia de combinación de anticuerpos contra csf-1r humano con un agonista de tlr9
RU2687043C2 (ru)	2013-04-29	2019-05-06	Ф. Хоффманн-Ля Рош Аг	МОДИФИЦИРОВАННЫЕ АСИММЕТРИЧНЫЕ АНТИТЕЛА, СВЯЗЫВАЮЩИЕ Fc-РЕЦЕПТОР, И СПОСОБЫ ИХ ПРИМЕНЕНИЯ
WO2014179657A1 (en)	2013-05-03	2014-11-06	Eleven Biotherapeutics, Inc.	Albumin variants binding to fcrn
WO2014189973A2 (en)	2013-05-20	2014-11-27	Genentech, Inc.	Anti-transferrin receptor antibodies and methods of use
EP3013365B1 (de)	2013-06-26	2019-06-05	Academia Sinica	Rm2-antigene und verwendung davon
WO2014210564A1 (en)	2013-06-27	2014-12-31	Academia Sinica	Glycan conjugates and use thereof
US20160168231A1 (en)	2013-07-18	2016-06-16	Fabrus, Inc.	Antibodies with ultralong complementarity determining regions
AU2014290361B2 (en)	2013-07-18	2019-04-18	Taurus Biosciences, Llc	Humanized antibodies with ultralong complementarity determining regions
JP6510518B2 (ja)	2013-08-01	2019-05-08	アジェンシス，インコーポレイテッド	Ｃｄ３７タンパク質に結合する抗体薬物結合体（ａｄｃ）
WO2015035044A2 (en)	2013-09-04	2015-03-12	Abbvie Biotherapeutics Inc.	Fc VARIANTS WITH IMPROVED ANTIBODY-DEPENDENT CELL-MEDIATED CYTOTOXICITY
US9782476B2 (en)	2013-09-06	2017-10-10	Academia Sinica	Human iNKT cell activation using glycolipids with altered glycosyl groups
AR097584A1 (es)	2013-09-12	2016-03-23	Hoffmann La Roche	Terapia de combinación de anticuerpos contra el csf-1r humano y anticuerpos contra el pd-l1 humano
WO2015042108A1 (en)	2013-09-17	2015-03-26	Genentech, Inc.	Methods of using anti-lgr5 antibodies
WO2015054427A1 (en)	2013-10-10	2015-04-16	Beth Israel Deaconess Medical Center, Inc.	Tm4sf1 binding proteins and methods of using same
CA2927022C (en)	2013-10-11	2018-08-21	Asana Biosciences, Llc	Protein-polymer-drug conjugates
SI3055331T1 (sl)	2013-10-11	2021-04-30	Oxford Bio Therapeutics Limited	Konjugirana protitelesa proti LY75 za zdravljenje raka
EA032231B1 (ru)	2013-10-11	2019-04-30	Мерсана Терапьютикс, Инк.	Конъюгаты белок-полимер-лекарственное средство
CN105744954B (zh)	2013-10-18	2021-03-05	豪夫迈·罗氏有限公司	抗rspo2和/或抗rspo3抗体及其用途
ES2768611T3 (es) *	2013-11-04	2020-06-23	Pfizer	Intermedios y procedimientos para sintetizar derivados de calicheamicina
CN105828841A (zh)	2013-11-04	2016-08-03	辉瑞大药厂	抗-efna4抗体-药物缀合物
EA201691214A1 (ru)	2013-12-13	2016-12-30	Дженентек, Инк.	Антитела к cd33 и иммуноконъюгаты
KR20170042495A (ko)	2013-12-16	2017-04-19	제넨테크, 인크.	펩티드모방체 화합물 및 그의 항체-약물 접합체
TWI728373B (zh)	2013-12-23	2021-05-21	美商建南德克公司	抗體及使用方法
PL3087182T3 (pl)	2013-12-23	2019-11-29	Memorial Sloan Kettering Cancer Center	Sposoby i kompozycje do leczenia raka wykorzystujące środki oparte na kwasie peptydonukleinowym
MX373856B (es)	2014-01-03	2020-03-25	Hoffmann La Roche	Conjugados helicoidales-anticuerpo anti-helicoidal unidos covalentemente y usos de los mismos.
CA2933384A1 (en)	2014-01-03	2015-07-09	F. Hoffmann-La Roche Ag	Bispecific anti-hapten/anti-blood brain barrier receptor antibodies, complexes thereof and their use as blood brain barrier shuttles
BR112016014945A2 (pt)	2014-01-03	2018-01-23	F. Hoffmann-La Roche Ag	conjugado, formulação farmacêutica e uso
US10150818B2 (en)	2014-01-16	2018-12-11	Academia Sinica	Compositions and methods for treatment and detection of cancers
CA2937123A1 (en)	2014-01-16	2015-07-23	Academia Sinica	Compositions and methods for treatment and detection of cancers
US20170043034A1 (en)	2014-01-24	2017-02-16	Genentech, Inc.	Methods of using anti-steap1 antibodies and immunoconjugates
JP2017510548A (ja)	2014-01-29	2017-04-13	シャンハイヘンルイファーマスーティカルカンパニーリミテッドＳｈａｎｇｈａｉＨｅｎｇｒｕｉＰｈａｒｍａｃｅｕｔｉｃａｌＣｏ．，Ｌｔｄ．	リガンド‐細胞傷害性薬物抱合体、その製造方法、およびその用途
JP6736467B2 (ja)	2014-02-04	2020-08-05	ジェネンテック，インコーポレイテッド	平滑化変異体及びその使用方法
PL3105253T3 (pl)	2014-02-12	2018-12-31	F. Hoffmann-La Roche Ag	Przeciwciała anty-Jagged1 i sposoby stosowania
JP2017507939A (ja)	2014-02-21	2017-03-23	ジェネンテック，インコーポレイテッド	抗ｉｌ−１３／ｉｌ−１７二重特異性抗体及びその使用
CA2938919C (en)	2014-02-28	2020-12-29	Hangzhou Dac Biotech Co., Ltd	Charged linkers and their uses for conjugation
EP3116999B1 (de)	2014-03-14	2021-09-15	F. Hoffmann-La Roche AG	Verfahren und zusammensetzungen für die sekretion von heterologen polypeptiden
TWI731535B (zh)	2014-03-21	2021-06-21	美商艾伯維有限公司	抗-egfr抗體及抗體藥物結合物
EP3119490B1 (de)	2014-03-21	2021-09-08	F. Hoffmann-La Roche AG	In-vitro-prognose von in-vivo-halbwertzeit von antikörpern
EP3122900A1 (de)	2014-03-24	2017-02-01	F. Hoffmann-La Roche AG	Krebsbehandlung mit c-met-antagonisten und korrelation desselben mit hgf-expression
WO2015148915A1 (en)	2014-03-27	2015-10-01	Academia Sinica	Reactive labelling compounds and uses thereof
JP6775422B2 (ja)	2014-03-28	2020-10-28	ゼンコー・インコーポレイテッドＸｅｎｃｏｒ、Ｉｎｃ．	Ｃｄ３８及びｃｄ３に結合する二重特異性抗体
RU2016142476A (ru)	2014-03-31	2018-05-07	Дженентек, Инк.	Комбинированная терапия, включающая антиангиогенезные агенты и агонисты, связывающие ох40
EP3126394B1 (de)	2014-03-31	2019-10-30	F.Hoffmann-La Roche Ag	Anti-ox40-antikörper und verfahren zur verwendung
MX2016012830A (es)	2014-04-11	2017-01-05	Medimmune Llc	Anticuerpos contra el receptor 2 del factor de crecimiento epidermico humano (her2) biespecificos.
EP3134438B1 (de)	2014-04-25	2020-09-30	Pierre Fabre Medicament	Igf-1r-antikörper und dessen verwendung als adressierungsmedium bei der behandlung von krebs
US9777070B2 (en)	2014-04-30	2017-10-03	Pfizer Inc	Anti-PTK7 antibody-drug conjugates
CA2943707A1 (en)	2014-05-06	2015-11-12	Genentech, Inc.	Production of heteromultimeric proteins using mammalian cells
WO2015179658A2 (en)	2014-05-22	2015-11-26	Genentech, Inc.	Anti-gpc3 antibodies and immunoconjugates
KR20170005016A (ko)	2014-05-23	2017-01-11	제넨테크, 인크.	MiT 바이오마커 및 그의 사용 방법
US10118969B2 (en)	2014-05-27	2018-11-06	Academia Sinica	Compositions and methods relating to universal glycoforms for enhanced antibody efficacy
KR102512592B1 (ko)	2014-05-27	2023-03-21	아카데미아 시니카	항-ｈｅｒ2 글리코항체 및 이의 용도
CA2950423A1 (en)	2014-05-27	2015-12-03	Academia Sinica	Compositions and methods relating to universal glycoforms for enhanced antibody efficacy
KR20170003720A (ko)	2014-05-27	2017-01-09	아카데미아 시니카	항-ｃｄ20 글리코항체 및 이의 용도
CN106714829A (zh)	2014-05-28	2017-05-24	中央研究院	抗TNF‑α醣抗体及其用途
CN107073121A (zh)	2014-06-13	2017-08-18	基因泰克公司	治疗及预防癌症药物抗性的方法
KR20170026362A (ko)	2014-06-26	2017-03-08	에프. 호프만-라 로슈 아게	항-ｂｒｄｕ 항체 및 사용 방법
CA2952315A1 (en)	2014-07-11	2016-01-14	Genentech, Inc.	Notch pathway inhibition
US20160060360A1 (en)	2014-07-24	2016-03-03	Xencor, Inc.	Rapid clearance of antigen complexes using novel antibodies
WO2016033331A1 (en)	2014-08-28	2016-03-03	Bioatla, Llc	Conditionally active chimeric antigen receptors for modified t-cells
TWI805109B (zh)	2014-08-28	2023-06-11	美商奇諾治療有限公司	對cd19具專一性之抗體及嵌合抗原受體
CA2960712A1 (en)	2014-09-08	2016-03-17	Academia Sinica	Human inkt cell activation using glycolipids
KR20170066421A (ko)	2014-09-12	2017-06-14	제넨테크, 인크.	항-cll-1 항체 및 면역접합체
JP6943760B2 (ja)	2014-09-12	2021-10-06	ジェネンテック，インコーポレイテッド	抗ｂ７−ｈ４抗体及び免疫複合体
LT3191135T (lt)	2014-09-12	2020-11-25	Genentech, Inc.	Anti-her2 antikūnai ir imunokonjugatai
MX2017003123A (es)	2014-09-12	2017-05-12	Genentech Inc	Anticuerpos y conjugados modificados geneticamente con cisteina.
PT3262071T (pt)	2014-09-23	2020-06-16	H Hoffnabb La Roche Ag	Métodos de utilização de imunoconjugados anti-cd79b
JP6863888B2 (ja)	2014-10-01	2021-04-21	メディミューン，エルエルシー	ポリペプチドをコンジュゲートさせる方法
US9732148B2 (en)	2014-10-16	2017-08-15	Genentech, Inc.	Anti-α-synuclein antibodies and methods of use
WO2016063959A1 (ja)	2014-10-24	2016-04-28	日油株式会社	環状ベンジリデンアセタールリンカーを有する抗体―薬物複合体
CN107148283A (zh)	2014-10-31	2017-09-08	豪夫迈·罗氏有限公司	抗il‑17a和il‑17f交叉反应性抗体变体、包含其的组合物及其制备和使用方法
MX2017005751A (es)	2014-11-03	2018-04-10	Genentech Inc	Métodos y biomarcadores para predecir la eficacia y evaluación de un tratamiento con agonista de ox40.
EP3215850B1 (de)	2014-11-03	2019-07-03	F. Hoffmann-La Roche AG	Tests zum nachweis von te-zell-immununtergruppen und verfahren zur verwendung davon
CA2961439A1 (en)	2014-11-05	2016-05-12	Genentech, Inc.	Anti-fgfr2/3 antibodies and methods using same
RS59340B1 (sr)	2014-11-06	2019-10-31	Hoffmann La Roche	Varijante fc regiona sa modifikovanim vezivanjem za fcrn i metode upotrebe
WO2016073157A1 (en)	2014-11-06	2016-05-12	Genentech, Inc.	Anti-ang2 antibodies and methods of use thereof
TWI705976B (zh)	2014-11-10	2020-10-01	美商建南德克公司	抗介白素-33抗體及其用途
EP3221361B1 (de)	2014-11-19	2021-04-21	Genentech, Inc.	Multispezifische anti-transferrin-rezeptor- / anti-bace1-antikörper und verfahren zur verwendung
WO2016081639A1 (en)	2014-11-19	2016-05-26	Genentech, Inc.	Antibodies against bace1 and use thereof for neural disease immunotherapy
EP3221362B1 (de)	2014-11-19	2019-07-24	F.Hoffmann-La Roche Ag	Anti-transferrin-rezeptor-antikörper und verfahren zur verwendung
US10259887B2 (en)	2014-11-26	2019-04-16	Xencor, Inc.	Heterodimeric antibodies that bind CD3 and tumor antigens
CN110894240B (zh)	2014-11-26	2022-04-15	森科股份有限公司	结合cd3和肿瘤抗原的异二聚体抗体
BR112017011166A2 (pt)	2014-11-26	2018-02-27	Xencor, Inc.	anticorpos heterodiméricos que se ligam a cd3 e cd38
CN107001482B (zh)	2014-12-03	2021-06-15	豪夫迈·罗氏有限公司	多特异性抗体
MA40938A (fr)	2014-12-05	2017-10-11	Hoffmann La Roche	Anticorps anti-cd79b et méthodes d'utilisation desdits anticorps
RU2017120039A (ru)	2014-12-10	2019-01-10	Дженентек, Инк.	Антитела к рецепторам гематоэнцефалического барьера и способы их применения
AU2015366284B2 (en)	2014-12-19	2021-07-22	Ablynx N.V.	Cysteine linked nanobody dimers
CN107207607B (zh)	2014-12-19	2021-05-04	中外制药株式会社	抗-c5抗体及使用方法
KR101860280B1 (ko)	2014-12-19	2018-05-21	추가이 세이야쿠 가부시키가이샤	항-마이오스타틴 항체, 변이체 Fc 영역을 함유하는 폴리펩타이드, 및 사용 방법
WO2016105450A2 (en)	2014-12-22	2016-06-30	Xencor, Inc.	Trispecific antibodies
JP6865688B2 (ja)	2015-01-16	2021-04-28	ジュノーセラピューティクスインコーポレイテッド	Ｒｏｒ１に特異的な抗体およびキメラ抗原受容体
US9975965B2 (en)	2015-01-16	2018-05-22	Academia Sinica	Compositions and methods for treatment and detection of cancers
US10495645B2 (en)	2015-01-16	2019-12-03	Academia Sinica	Cancer markers and methods of use thereof
GB201501004D0 (en)	2015-01-21	2015-03-04	Cancer Rec Tech Ltd	Inhibitors
CN107428823B (zh)	2015-01-22	2021-10-26	中外制药株式会社	两种以上抗-c5抗体的组合与使用方法
JP2018510844A (ja)	2015-01-24	2018-04-19	アカデミアシニカＡｃａｄｅｍｉａＳｉｎｉｃａ	がんマーカーおよびその使用方法
AU2015378564A1 (en)	2015-01-24	2017-07-13	Academia Sinica	Novel glycan conjugates and methods of use thereof
US10441649B2 (en)	2015-02-02	2019-10-15	The University Of Birmingham	Targeting moiety peptide epitope complexes having a plurality of T-cell epitopes
CA2975875A1 (en)	2015-02-04	2016-08-11	Genentech, Inc.	Mutant smoothened and methods of using the same
CN114773470A (zh)	2015-02-05	2022-07-22	中外制药株式会社	包含离子浓度依赖性的抗原结合结构域的抗体，fc区变体，il-8-结合抗体及其应用
WO2016141387A1 (en)	2015-03-05	2016-09-09	Xencor, Inc.	Modulation of t cells with bispecific antibodies and fc fusions
JP2018515457A (ja) *	2015-04-21	2018-06-14	アッヴィ・ステムセントルクス・エル・エル・シー	カリケアマイシン構築物および使用方法
EP3286315B1 (de)	2015-04-24	2021-05-26	F. Hoffmann-La Roche AG	Verfahren zur identifizierung von bakterien mit bindenden polypeptiden
AU2016252773B2 (en)	2015-04-24	2022-06-02	Genentech, Inc.	Multispecific antigen-binding proteins
EP3778640A1 (de)	2015-05-01	2021-02-17	Genentech, Inc.	Maskierte anti-cd3-antikörper und verfahren zur verwendung
WO2016183104A1 (en)	2015-05-11	2016-11-17	Genentech, Inc.	Compositions and methods of treating lupus nephritis
RS61152B2 (sr)	2015-05-12	2024-06-28	Hoffmann La Roche	Terapeutski i dijagnostički postupci za lečenje raka
JP7144935B2 (ja)	2015-05-29	2022-09-30	ジェネンテック，インコーポレイテッド	癌のための治療方法及び診断方法
WO2016196343A1 (en)	2015-05-29	2016-12-08	Genentech, Inc.	Humanized anti-ebola virus glycoprotein antibodies and methods of use
KR20180011839A (ko)	2015-06-08	2018-02-02	제넨테크, 인크.	항-ox40 항체를 이용한 암의 치료 방법
HK1251474A1 (zh)	2015-06-08	2019-02-01	豪夫迈‧罗氏有限公司	使用抗ox40抗体和pd-1轴结合拮抗剂治疗癌症的方法
EP3310378B1 (de)	2015-06-16	2024-01-24	F. Hoffmann-La Roche AG	Anti-cll-1-antikörper und verfahren zur verwendung
TWI731861B (zh)	2015-06-16	2021-07-01	美商建南德克公司	FcRH5之人源化及親和力成熟抗體及使用方法
EP3916018A1 (de)	2015-06-16	2021-12-01	Genentech, Inc.	Anti-cd3-antikörper und verfahren zur verwendung
CN107787331B (zh)	2015-06-17	2022-01-11	豪夫迈·罗氏有限公司	抗her2抗体和使用方法
MX391086B (es)	2015-06-24	2025-03-21	Hoffmann La Roche	Anticuerpos anti-receptor de transferrina con afinidad diseñada.
WO2016207091A1 (en)	2015-06-24	2016-12-29	F. Hoffmann-La Roche Ag	Trispecific antibodies specific for her2 and a blood brain barrier receptor and methods of use
KR20180021864A (ko)	2015-06-29	2018-03-05	제넨테크, 인크.	장기 이식에서 사용하기 위한 유형 ii 항-cd20 항체
FI3319936T3 (fi)	2015-07-12	2026-03-12	Hangzhou Dac Biotech Co Ltd	Silloituslinkkereitä soluun sitoutuvien molekyylien konjugoimiseksi
US9839687B2 (en)	2015-07-15	2017-12-12	Suzhou M-Conj Biotech Co., Ltd.	Acetylenedicarboxyl linkers and their uses in specific conjugation of a cell-binding molecule
PE20180802A1 (es)	2015-08-05	2018-05-09	Janssen Biotech Inc	Anticuerpos anti-cd154 y metodos de uso de estos
CN105384825B (zh)	2015-08-11	2018-06-01	南京传奇生物科技有限公司	一种基于单域抗体的双特异性嵌合抗原受体及其应用
WO2017029407A1 (en)	2015-08-20	2017-02-23	Albumedix A/S	Albumin variants and conjugates
CA3289997A1 (en)	2015-09-20	2026-03-02	The United States Of America, As Represented By The Secretary, Department Of Health And Human Services	Monoclonal Antibodies Specific for Fibroblast Growth Factor Receptor 4 (FGFR4) and Methods of Their Use
RU2763916C2 (ru)	2015-09-23	2022-01-11	Дженентек, Инк.	Оптимизированные варианты анти-vegf антител
AU2016326738B2 (en)	2015-09-24	2023-08-31	Abvitro Llc	HIV antibody compositions and methods of use
CA2994858C (en)	2015-09-25	2024-01-23	Genentech, Inc.	Anti-tigit antibodies and methods of use
CR20180177A (es)	2015-09-30	2018-06-22	Janssen Biotech Inc	Anticuerpos agonistas que se unen específicamente a cd40 humana y método de uso
NZ739090A (en)	2015-10-02	2025-06-27	Hoffmann La Roche	Bispecific antibodies specific for pd1 and tim3
AR106189A1 (es)	2015-10-02	2017-12-20	Hoffmann La Roche	ANTICUERPOS BIESPECÍFICOS CONTRA EL A-b HUMANO Y EL RECEPTOR DE TRANSFERRINA HUMANO Y MÉTODOS DE USO
NZ741067A (en)	2015-10-02	2023-07-28	Hoffmann La Roche	Bispecific anti-human cd20/human transferrin receptor antibodies and methods of use
CR20180151A (es)	2015-10-02	2018-05-25	Hoffmann La Roche	Antcuierpos anti-pd1 y métodos de uso
EP3362100B1 (de)	2015-10-16	2022-06-22	Genentech, Inc.	Gehinderte disulfidwirkstoffkonjugate
EP3365025B1 (de)	2015-10-20	2020-07-15	Genentech, Inc.	Calicheamicin-antikörper-arzneimittelkonjugate und verfahren zur verwendung
EP3184547A1 (de)	2015-10-29	2017-06-28	F. Hoffmann-La Roche AG	Anti-tpbg-antikörper und verfahren zur verwendung
ES2904553T3 (es)	2015-10-30	2022-04-05	Hoffmann La Roche	Fragmentos de anticuerpo modificados con bisagra y procedimientos de preparación
EP3370768B9 (de)	2015-11-03	2022-03-16	Janssen Biotech, Inc.	Spezifisch an pd-1 bindende antikörper und deren verwendung
EP3371217B1 (de)	2015-11-08	2025-06-11	F. Hoffmann-La Roche AG	Screening verfahren für multispezifische antikörper
ES2873846T5 (en)	2015-11-19	2025-06-23	Revitope Ltd	Functional antibody fragment complementation for a two-components system for redirected killing of unwanted cells
EP3383920B1 (de)	2015-11-30	2024-01-10	The Regents of the University of California	Freisetzung von tumorspezifischer nutzlast und immunaktivierung mit einem menschlichen antikörper gegen hochspezifisches tumorzellenoberflächenantigen
JP7058219B2 (ja)	2015-12-07	2022-04-21	ゼンコアインコーポレイテッド	Ｃｄ３及びｐｓｍａに結合するヘテロ二量体抗体
EP3178848A1 (de)	2015-12-09	2017-06-14	F. Hoffmann-La Roche AG	Type ii anti-cd20 antikörper zur verringerung der bildung von antikörpern gegen medikamente
EP4026848A1 (de)	2015-12-09	2022-07-13	F. Hoffmann-La Roche AG	Type ii anti-cd20 antikörper zur reduktion des zytokin-freisetzungssyndroms
TWI605057B (zh)	2015-12-18	2017-11-11	中外製藥股份有限公司	抗肌抑素抗體、含變異ｆｃ區之多肽及使用方法
IL259256B2 (en)	2015-12-18	2023-02-01	Chugai Pharmaceutical Co Ltd	Anti-c5 antibodies and methods of use
CN108495653A (zh)	2016-01-27	2018-09-04	免疫医疗有限责任公司	用于制备具有定义的糖基化模式抗体的方法
JP2019509721A (ja)	2016-02-04	2019-04-11	キュリス，インコーポレイテッド	突然変異体スムースンド及びその使用方法
CA3252097A1 (en)	2016-02-05	2026-03-02	The University Of Copenhagen	ANTIBODY-DRUG CONJUGATES TARGETING uPARAP
JP6821693B2 (ja)	2016-02-29	2021-01-27	ジェネンテック，インコーポレイテッド	がんのための治療方法及び診断方法
US11340233B2 (en)	2016-03-07	2022-05-24	Pierre Fabre Medicament	Universal method to capture and analyze ADCs for characterization of drug distribution and the drug-to-antibody ratio in biological samples
WO2017156192A1 (en)	2016-03-08	2017-09-14	Academia Sinica	Methods for modular synthesis of n-glycans and arrays thereof
WO2017172907A1 (en) *	2016-03-29	2017-10-05	Sorrento Therapeutics, Inc.	Calicheamicin antibody drug conjugates linking an amidoacetyl group to a sugar moiety on calicheamicin
KR102466763B1 (ko)	2016-04-13	2022-11-11	오리맵스 리미티드	항- psma 항체 및 이의 용도
EP3443004A1 (de)	2016-04-14	2019-02-20	H. Hoffnabb-La Roche Ag	Anti-rspo3-antikörper und verfahren zur verwendung
CN109154613A (zh)	2016-04-15	2019-01-04	豪夫迈·罗氏有限公司	用于监测和治疗癌症的方法
TWI781098B (zh)	2016-04-15	2022-10-21	美商宏觀基因股份有限公司	新穎的ｂ７-ｈ３-結合分子、其抗體藥物綴合物及其使用方法
PL3443012T3 (pl)	2016-04-15	2026-04-20	Bioatla, Inc.	Przeciwciała anty-axl, fragmenty przeciwciał i ich immunokoniugaty oraz ich zastosowania
AU2017248766A1 (en)	2016-04-15	2018-11-01	Genentech, Inc.	Methods for monitoring and treating cancer
AU2017259869A1 (en)	2016-05-02	2018-09-27	F. Hoffmann-La Roche Ag	The contorsbody - a single chain target binder
WO2017196847A1 (en)	2016-05-10	2017-11-16	The United States Of America, As Represented By The Secretary, Department Of Health And Human Services	Variable new antigen receptor (vnar) antibodies and antibody conjugates targeting tumor and viral antigens
WO2017194441A1 (en)	2016-05-11	2017-11-16	F. Hoffmann-La Roche Ag	Modified anti-tenascin antibodies and methods of use
CN116751298A (zh)	2016-05-13	2023-09-15	生物蛋白有限公司	抗ror2抗体、抗体片段和它们的免疫缀合物以及其用途
EP3465221B1 (de)	2016-05-27	2020-07-22	H. Hoffnabb-La Roche Ag	Bioanalytisches verfahren zur charakterisierung von ortsspezifischen antikörper-wirkstoff-konjugaten
US10668166B2 (en)	2016-05-30	2020-06-02	Toxinvent Ou	Antibody-drug-conjugates comprising novel anthracycline-derivatives for cancer treatment
EP3252078A1 (de)	2016-06-02	2017-12-06	F. Hoffmann-La Roche AG	Typ ii anti-cd20 antikörper und anti-cd20/cd3 bispecific antikörper zur behandlung von krebs
TW201902512A (zh)	2016-06-02	2019-01-16	瑞士商赫孚孟拉羅股份公司	治療方法
WO2017214182A1 (en)	2016-06-07	2017-12-14	The United States Of America. As Represented By The Secretary, Department Of Health & Human Services	Fully human antibody targeting pdi for cancer immunotherapy
BR112018075644A2 (pt)	2016-06-08	2019-04-09	Abbvie Inc.	anticorpos anti-cd98 e conjugados de anticorpo e fármaco
JP2019526529A (ja)	2016-06-08	2019-09-19	アッヴィ・インコーポレイテッド	抗ｂ７−ｈ３抗体及び抗体薬物コンジュゲート
BR112018075630A2 (pt)	2016-06-08	2019-03-19	Abbvie Inc.	anticorpos anti-cd98 e conjugados de fármaco de anticorpo
EP3458479B1 (de)	2016-06-08	2020-11-04	AbbVie Inc.	Anti-b7-h3-antikörper und antikörper-wirkstoff-konjugate
EP3469000A1 (de)	2016-06-08	2019-04-17	AbbVie Inc.	Anti-b7-h3-antikörper und antikörperarzneimittelkonjugate
EP3468997B1 (de)	2016-06-08	2023-09-13	Xencor, Inc.	Behandlung von erkrankungen im zusammenhang mit igg4 mit anti-cd19-antikörpern mit kreuzbindung an cd32b
SI3468586T1 (sl)	2016-06-14	2025-01-31	Xencor, Inc.	Bispecifična protitelesa za zaviralce kontrolnih točk
KR102306744B1 (ko)	2016-06-17	2021-09-28	추가이 세이야쿠 가부시키가이샤	항-마이오스타틴 항체 및 사용 방법
US11617799B2 (en)	2016-06-27	2023-04-04	Tagworks Pharmaceuticals B.V.	Cleavable tetrazine used in bio-orthogonal drug activation
WO2018005706A1 (en)	2016-06-28	2018-01-04	Xencor, Inc.	Heterodimeric antibodies that bind somatostatin receptor 2
WO2018009811A1 (en)	2016-07-08	2018-01-11	Genentech, Inc.	Use of human epididymis protein 4 (he4) for assessing responsiveness of muc 16-positive cancer treatment
US20240018268A1 (en)	2016-07-29	2024-01-18	Juno Therapeutics, Inc.	Anti-idiotypic antibodies against anti-cd19 antibodies
EP3494135A1 (de)	2016-08-02	2019-06-12	The United States of America, as represented by The Secretary, Department of Health and Human Services	Gegen glypican-2 (gpc2) gerichtete monoklonale antikörper und verwendung davon
WO2018025168A1 (en)	2016-08-03	2018-02-08	Pfizer Inc.	Heteroaryl sulfone-based conjugation handles, methods for their preparation, and their use in synthesizing antibody drug conjugates
US11046776B2 (en)	2016-08-05	2021-06-29	Genentech, Inc.	Multivalent and multiepitopic antibodies having agonistic activity and methods of use
TWI693940B (zh)	2016-08-05	2020-05-21	日商中外製藥股份有限公司	Ｉｌ-８相關疾病之治療用或預防用組成物
EP4282877A3 (de)	2016-08-10	2024-02-21	Legend Biotech Ireland Limited	Gegen bcma gerichtete chimäre antigenrezeptoren und verfahren zur verwendung davon
EP3500594A4 (de)	2016-08-22	2020-03-11	Cho Pharma Inc.	Antikörper, bindungsfragmente und verfahren zur verwendung
CN109790220A (zh)	2016-08-25	2019-05-21	豪夫迈·罗氏有限公司	与巨噬细胞激活剂组合的抗csf-1r抗体的间歇给药
US10793632B2 (en)	2016-08-30	2020-10-06	Xencor, Inc.	Bispecific immunomodulatory antibodies that bind costimulatory and checkpoint receptors
SG10201607778XA (en)	2016-09-16	2018-04-27	Chugai Pharmaceutical Co Ltd	Anti-Dengue Virus Antibodies, Polypeptides Containing Variant Fc Regions, And Methods Of Use
CN116731197A (zh)	2016-09-19	2023-09-12	豪夫迈·罗氏有限公司	基于补体因子的亲和层析
AU2017339517B2 (en)	2016-10-06	2024-03-14	Foundation Medicine, Inc.	Therapeutic and diagnostic methods for cancer
CN110214147A (zh)	2016-10-14	2019-09-06	Xencor股份有限公司	IL15/IL15Rα异源二聚体FC-融合蛋白
KR20240000650A (ko)	2016-10-19	2024-01-02	인벤라 인코포레이티드	항체 구조물
EP3532091A2 (de)	2016-10-29	2019-09-04	H. Hoffnabb-La Roche Ag	Anti-mic-antikörper und verfahren zur verwendung
CA3042442C (en)	2016-11-14	2024-01-02	Hangzhou Dac Biotech Co., Ltd	Conjugation linkers, cell binding molecule-drug conjugates containing the linkers, methods of making and uses of such conjugates with the linkers
WO2018093821A1 (en)	2016-11-15	2018-05-24	Genentech, Inc.	Dosing for treatment with anti-cd20/anti-cd3 bispecific antibodies
TW201829463A (zh)	2016-11-18	2018-08-16	瑞士商赫孚孟拉羅股份公司	抗hla-g抗體及其用途
JP7313684B2 (ja)	2016-11-21	2023-07-25	キュレアブゲーエムベーハー	抗ｇｐ７３抗体及びイムノコンジュゲート
US11135307B2 (en)	2016-11-23	2021-10-05	Mersana Therapeutics, Inc.	Peptide-containing linkers for antibody-drug conjugates
AU2017382883B2 (en)	2016-12-21	2024-07-04	The United States Of America, As Represented By The Secretary, Department Of Health And Human Services	Human monoclonal antibodies specific for FLT3 and uses thereof
CN110072553B (zh)	2016-12-22	2023-09-15	豪夫迈·罗氏有限公司	在抗pd-l1/pd1治疗失败之后抗csf-1r抗体与抗pd-l1抗体组合对肿瘤的治疗
EP3559039A1 (de)	2016-12-22	2019-10-30	Università Degli Studi Magna Graecia Catanzaro	Gegen ein eindeutiges sialoglycosyliertes krebsassoziiertes epitop von cd43 gerichteter monoklonaler antikörper
MX2019008773A (es) *	2017-01-24	2019-09-18	Pfizer	Derivados de caliqueamicina y conjugados anticuerpo-farmaco de los mismos.
PE20191548A1 (es)	2017-02-10	2019-10-24	Genentech Inc	Anticuerpos contra triptasa, composiciones de estos y usos de estos
CN110546277B (zh)	2017-03-01	2024-06-11	豪夫迈·罗氏有限公司	用于癌症的诊断和治疗方法
EP3615572A1 (de)	2017-04-27	2020-03-04	Tesaro Inc.	Gegen lymphozytenaktivierungsgen 3 (lag-3) gerichtete antikörpermittel und verwendungen davon
WO2018213064A1 (en)	2017-05-19	2018-11-22	The United States Of America, As Represented By The Secretary, Department Of Health And Human Services	Human monoclonal antibody targeting tnfer2 for cancer immunotherapy
AR111963A1 (es)	2017-05-26	2019-09-04	Univ California	Método y moléculas
JP7320458B2 (ja)	2017-06-22	2023-08-03	メルサナセラピューティクスインコーポレイテッド	薬物担持ポリマースキャフォールドおよびタンパク質－ポリマー－薬物コンジュゲートを製造する方法
CA3066953A1 (en)	2017-06-30	2019-01-03	Lentigen Technology, Inc.	Human monoclonal antibodies specific for cd33 and methods of their use
US11084863B2 (en)	2017-06-30	2021-08-10	Xencor, Inc.	Targeted heterodimeric Fc fusion proteins containing IL-15 IL-15alpha and antigen binding domains
WO2019005208A1 (en)	2017-06-30	2019-01-03	The United States Of America, As Represented By The Secretary, Department Of Health And Human Services	ANTIBODIES TO HUMAN MESOTHELIN AND USES IN ANTICANCER THERAPY
WO2019018647A1 (en)	2017-07-20	2019-01-24	Pfizer Inc.	ANTI-GD3 ANTIBODIES AND CONJUGATES ANTIBODY-MEDICATION
KR102922386B1 (ko)	2017-07-21	2026-02-04	제넨테크, 인크.	암에 대한 치료 및 진단 방법
WO2019078357A1 (ja)	2017-10-20	2019-04-25	中外製薬株式会社	細胞への分子の取り込みを測定する方法
CA3079215A1 (en)	2017-10-24	2019-05-02	Magenta Therapeutics, Inc.	Compositions and methods for the depletion of cd117+ cells
BR112020007736A2 (pt)	2017-10-30	2020-10-20	F. Hoffmann-La Roche Ag	composição e método de tratamento
PL3704146T3 (pl)	2017-11-01	2022-03-07	F. Hoffmann-La Roche Ag	Przeciwciało Contorsbody trifab
JP2021500930A (ja)	2017-11-01	2021-01-14	エフ．ホフマン−ラロシュアーゲーＦ．Ｈｏｆｆｍａｎｎ−ＬａＲｏｃｈｅＡｋｔｉｅｎｇｅｓｅｌｌｓｃｈａｆｔ	Ｃｏｍｐボディ−多価標的結合物質
AU2018358067A1 (en)	2017-11-01	2020-05-07	Juno Therapeutics, Inc.	Antibodies and chimeric antigen receptors specific for B-cell maturation antigen
ES2984919T3 (es)	2017-11-06	2024-10-31	Hoffmann La Roche	Procedimientos diagnósticos y terapéuticos para el cáncer
US10981992B2 (en)	2017-11-08	2021-04-20	Xencor, Inc.	Bispecific immunomodulatory antibodies that bind costimulatory and checkpoint receptors
JP2021502100A (ja)	2017-11-08	2021-01-28	ゼンコアインコーポレイテッド	新規抗ｐｄ−１配列を用いた二重特異性および単一特異性抗体
EP3710589A4 (de)	2017-11-14	2021-11-10	Chugai Seiyaku Kabushiki Kaisha	Anti-c1s-antikörper und verfahren zur verwendung
WO2019108863A1 (en)	2017-11-29	2019-06-06	Magenta Therapeutics, Inc.	Compositions and methods for the depletion of cd5+ cells
US11319355B2 (en)	2017-12-19	2022-05-03	Xencor, Inc.	Engineered IL-2 Fc fusion proteins
US11667713B2 (en)	2017-12-28	2023-06-06	Chugai Seiyaku Kabushiki Kaisha	Cytotoxicity-inducing therapeutic agent
EP3737692A4 (de)	2018-01-09	2021-09-29	Elstar Therapeutics, Inc.	Calreticulin-bindende konstrukte und gentechnisch veränderte t-zellen zur behandlung von krankheiten
EP3740505A1 (de)	2018-01-16	2020-11-25	Lakepharma Inc.	Bispezifischer antikörper, der cd3 und ein anderes ziel bindet
US12398209B2 (en)	2018-01-22	2025-08-26	Janssen Biotech, Inc.	Methods of treating cancers with antagonistic anti-PD-1 antibodies
JP7475275B2 (ja)	2018-02-08	2024-04-26	ジェネンテック，インコーポレイテッド	二重特異性抗原結合分子及びその使用方法
CN111836831A (zh)	2018-02-26	2020-10-27	豪夫迈·罗氏有限公司	用于抗tigit拮抗剂抗体和抗pd-l1拮抗剂抗体治疗的给药
US20200040103A1 (en)	2018-03-14	2020-02-06	Genentech, Inc.	Anti-klk5 antibodies and methods of use
US12152073B2 (en)	2018-03-14	2024-11-26	Marengo Therapeutics, Inc.	Multifunctional molecules that bind to calreticulin and uses thereof
CN111918877A (zh)	2018-03-14	2020-11-10	美国卫生和人力服务部	抗cd33嵌合抗原受体及其用途
CA3093729A1 (en)	2018-03-15	2019-09-19	Chugai Seiyaku Kabushiki Kaisha	Anti-dengue virus antibodies having cross-reactivity to zika virus and methods of use
JP7104458B2 (ja)	2018-04-02	2022-07-21	上海博威生物医薬有限公司	リンパ球活性化遺伝子－３（ｌａｇ－３）結合抗体およびその使用
TW202011029A (zh)	2018-04-04	2020-03-16	美商建南德克公司	偵測及定量fgf21之方法
WO2019195623A2 (en)	2018-04-04	2019-10-10	Xencor, Inc.	Heterodimeric antibodies that bind fibroblast activation protein
AR114789A1 (es)	2018-04-18	2020-10-14	Hoffmann La Roche	Anticuerpos anti-hla-g y uso de los mismos
SG11202010163QA (en)	2018-04-18	2020-11-27	Xencor Inc	Pd-1 targeted heterodimeric fusion proteins containing il-15/il-15ra fc-fusion proteins and pd-1 antigen binding domains and uses thereof
US11505595B2 (en)	2018-04-18	2022-11-22	Xencor, Inc.	TIM-3 targeted heterodimeric fusion proteins containing IL-15/IL-15RA Fc-fusion proteins and TIM-3 antigen binding domains
EP3787691A1 (de)	2018-05-04	2021-03-10	Tagworks Pharmaceuticals B.V.	Tetrazine für hohe clickkonjugationsausbeute in vivo und hohe clickfreisetzungsausbeute
ES2975330T3 (es)	2018-05-04	2024-07-04	Tagworks Pharmaceuticals B V	Compuestos que comprenden un enlazador para aumentar la estabilidad del trans-cicloocteno
AU2019271148B9 (en)	2018-05-14	2025-05-29	Werewolf Therapeutics, Inc.	Activatable interleukin-2 polypeptides and methods of use thereof
CA3100005A1 (en)	2018-05-14	2019-11-21	Werewolf Therapeutics, Inc.	Activatable cytokine polypeptides and methods of use thereof
SG11202011633SA (en)	2018-05-24	2020-12-30	Janssen Biotech Inc	Psma binding agents and uses thereof
WO2019234136A1 (en)	2018-06-05	2019-12-12	King's College London	Btnl3/8 targeting constructs for delivery of payloads to the gastrointestinal system
TW202519260A (zh)	2018-07-02	2025-05-16	美商安進公司	抗steap1抗原結合蛋白
EP3818083A2 (de)	2018-07-03	2021-05-12	Elstar Therapeutics, Inc.	Anti-tcr-antikörpermoleküle und ihre verwendungen
EP3820903A1 (de)	2018-07-12	2021-05-19	The United States of America, as represented by the Secretary, Department of Health and Human Services	Affinitätsgereifter cd22-spezifischer monoklonaler antikörper und seine verwendungen
CA3107383A1 (en)	2018-07-23	2020-01-30	Magenta Therapeutics, Inc.	Use of anti-cd5 antibody drug conjugate (adc) in allogeneic cell therapy
CN112585163B (zh)	2018-08-08	2025-03-25	美国政府(由卫生和人类服务部的部长所代表)	靶向磷脂酰肌醇蛋白聚糖-2的高亲和力单克隆抗体及其用途
EP3835321A4 (de)	2018-08-10	2022-11-02	Chugai Seiyaku Kabushiki Kaisha	Anti-cd137-antigen-bindendes molekül und verwendung davon
US12097219B2 (en)	2018-09-10	2024-09-24	Legend Biotech Ireland Limited	Single-domain antibodies against CLL1 and constructs thereof
EP3849565A4 (de)	2018-09-12	2022-12-28	Fred Hutchinson Cancer Research Center	Verminderung der cd33-expression zum selektiven schutz von therapeutischen zellen
JP2022501332A (ja)	2018-09-19	2022-01-06	ジェネンテック，インコーポレイテッド	膀胱がんの治療方法および診断方法
WO2020063676A1 (zh)	2018-09-26	2020-04-02	江苏恒瑞医药股份有限公司	依喜替康类似物的配体-药物偶联物及其制备方法和应用
CN120463822A (zh)	2018-09-27	2025-08-12	西里欧发展公司	掩蔽型细胞因子多肽
EP3861016A2 (de)	2018-10-03	2021-08-11	Xencor, Inc.	Il-12-heterodimere fc-fusionsproteine
MX2021004348A (es)	2018-10-18	2021-05-28	Genentech Inc	Procedimientos de diagnóstico y terapéuticos para el cáncer de riñón sarcomatoide.
AU2019369340A1 (en)	2018-10-29	2021-05-20	Mersana Therapeutics, Inc.	Cysteine engineered antibody-drug conjugates with peptide-containing linkers
EP3873519A1 (de)	2018-10-29	2021-09-08	F. Hoffmann-La Roche AG	Antikörperformulierung
SG11202103832SA (en)	2018-11-07	2021-05-28	Crispr Therapeutics Ag	Anti-cd33 immune cell cancer therapy
US11279698B2 (en)	2018-11-20	2022-03-22	Cornell University	Macrocyclic complexes of alpha-emitting radionuclides and their use in targeted radiotherapy of cancer
KR20210100668A (ko)	2018-12-06	2021-08-17	제넨테크, 인크.	항-CD79b 면역접합체, 알킬화제 및 항-CD20 항체를 포함하는 미만성 큰 B-세포 림프종의 조합 요법
AR117453A1 (es)	2018-12-20	2021-08-04	Genentech Inc	Fc de anticuerpos modificados y métodos para utilizarlas
WO2020127968A1 (en)	2018-12-20	2020-06-25	Marino Stephen F	Protein-drug conjugate comprising a monomeric form of proteinase 3
BR112021012536A2 (pt)	2018-12-26	2021-09-14	City Of Hope	Proteínas de ligação anti-ctla4 mascaradas ativáveis
US12180296B2 (en)	2019-01-08	2024-12-31	The United States Of America, As Represented By The Secretary, Department Of Health And Human Services	Cross species single domain antibodies targeting mesothelin for treating solid tumors
WO2020154150A1 (en)	2019-01-22	2020-07-30	The United States Of America, As Represented By The Secretary, Department Of Health And Human Services	High affinity monoclonal antibodies targeting glypican-1 and methods of use
BR112021014276A2 (pt)	2019-01-22	2021-09-28	Genentech, Inc.	Anticorpos iga isolados, moléculas de fusão igg-iga isoladas, ácido nucleico isolado, célula hospedeira, método para produzir um anticorpo, para tratar um indivíduo, para aumentar a expressão de dímeros, trímeros ou tetrâmeros, para aumentar a produção de polímeros, para aumentar a produção de dímeros, para aumentar a produção de um polímero, para diminuir a produção de polímeros, para aumentar a expressão transitória de um anticorpo, para expressar dímeros de moléculas de fusão, para expressar dímeros, trímeros ou tetrâmeros, para purificar um anticorpo, para purificar um estado oligomérico de um anticorpo, composição farmacêutica e uso do anticorpo
WO2020153467A1 (ja)	2019-01-24	2020-07-30	中外製薬株式会社	新規がん抗原及びそれらの抗原に対する抗体
CA3123303A1 (en)	2019-01-29	2020-08-06	Juno Therapeutics, Inc.	Antibodies and chimeric antigen receptors specific for receptor tyrosine kinase like orphan receptor 1 (ror1)
AU2020224681A1 (en)	2019-02-21	2021-09-16	Marengo Therapeutics, Inc.	Antibody molecules that bind to NKp30 and uses thereof
JP7710373B2 (ja)	2019-02-21	2025-07-18	マレンゴ・セラピューティクス，インコーポレーテッド	Ｔ細胞関連のがん細胞に結合する多機能性分子およびその使用
KR20210133237A (ko)	2019-02-27	2021-11-05	제넨테크, 인크.	항-tigit 및 항-cd20 또는 항-cd38 항체로 치료를 위한 투약
UA128825C2 (uk)	2019-03-01	2024-10-30	Ксенкор, Інк.	Гетеродимерні антитіла, що зв'язують enpp3 та cd3
TW202100556A (zh)	2019-03-14	2021-01-01	美商建南德克公司	使用her2 t細胞依賴性雙特異性抗體之治療
CN120131907A (zh)	2019-03-19	2025-06-13	瓦尔希伯伦私人肿瘤研究基金会	采用Omomyc和结合PD-1或CTLA-4的抗体治疗癌症的联合疗法
BR112021020532A2 (pt)	2019-04-19	2022-03-15	Janssen Biotech Inc	Métodos para tratamento de câncer de próstata com um anticorpo anti-psma/cd3
BR112021020867A2 (pt)	2019-04-19	2022-01-04	Genentech Inc	Anticorpos, ácido nucleico, vetor, célula hospedeira, método de produção de um anticorpo, imunoconjugado, formulação farmacêutica, usos do anticorpo, método de tratamento de um indivíduo com câncer e método para reduzir a depuração
EP3962527A4 (de)	2019-04-30	2023-11-01	Senti Biosciences, Inc.	Chimäre rezeptoren und verfahren zur verwendung davon
KR20220023988A (ko)	2019-05-14	2022-03-03	웨어울프 세라퓨틱스, 인크.	분리 모이어티 및 이의 사용 방법
KR20220007136A (ko)	2019-05-14	2022-01-18	제넨테크, 인크.	소포 림프종을 치료하기 위한 항-CD79b 면역접합체의 사용 방법
MX2021013441A (es)	2019-05-15	2021-12-10	Chugai Pharmaceutical Co Ltd	Molecula de union a antigenos, composicion farmaceutica y metodo.
BR112021024438A2 (pt)	2019-06-03	2022-02-15	Univ Chicago	Métodos e composições para tratar câncer com carreadores de fármaco de ligação de colágeno
WO2020248065A1 (en) *	2019-06-12	2020-12-17	Ontario Institute For Cancer Research (Oicr)	Unsaturated heterocycloalkyl and heteroaromatic acyl hydrazone linkers, methods and uses thereof
IL289094A (en)	2019-06-17	2022-02-01	Tagworks Pharmaceuticals B V	Tetrazines for increasing the speed and yield of the "click release" reaction
EP4382129A3 (de)	2019-06-17	2024-07-03	Tagworks Pharmaceuticals B.V.	Verbindungen für schnelle und effiziente klick-freigabe
CR20220049A (es)	2019-07-10	2022-03-02	Chugai Pharmaceutical Co Ltd	Moléculas de unión a claudina-6 y usos de las mismas
JPWO2021010326A1 (de)	2019-07-12	2021-01-21
KR20220070433A (ko)	2019-08-14	2022-05-31	코디악 바이오사이언시즈, 인크.	Stat6을 표적으로 하는 세포외 소포-aso 작제물
EP4013876A1 (de)	2019-08-14	2022-06-22	Codiak BioSciences, Inc.	Extrazelluläre vesikel mit nlrp3-antagonist
CA3147366A1 (en)	2019-08-14	2021-02-18	Adam T. BOUTIN	Extracellular vesicles with stat3-antisense oligonucleotides
AU2020330133A1 (en)	2019-08-14	2022-03-17	Lonza Sales Ag	Extracellular vesicle-ASO constructs targeting CEBP/beta
US20220306736A1 (en)	2019-09-04	2022-09-29	Y-Biologics Inc.	Anti-vsig4 antibody or antigen binding fragment and uses thereof
EP4048693A1 (de)	2019-09-27	2022-08-31	F. Hoffmann-La Roche AG	Dosieren zur behandlung mit anti-tigit- und anti-pd-l1-antagonist-antikörpern
WO2021066869A1 (en)	2019-10-04	2021-04-08	TAE Life Sciences	Antibody compositions comprising fc mutations and site-specific conjugation properties
CN114945386A (zh)	2019-10-18	2022-08-26	基因泰克公司	使用抗CD79b免疫缀合物治疗弥漫性大B细胞淋巴瘤的方法
CN114729041B (zh)	2019-10-22	2024-12-31	美国政府(由卫生和人类服务部的部长所代表)	用于治疗多种实体瘤的靶向b7h3（cd276）的高亲和力纳米抗体
AU2020378330A1 (en)	2019-11-06	2022-05-12	F. Hoffmann-La Roche Ag	Diagnostic and therapeutic methods for treatment of hematologic cancers
BR112022009110A2 (pt)	2019-11-14	2022-07-26	Werewolf Therapeutics Inc	Polipeptídeos de citocina ativáveis e métodos de uso destes
JP7762718B2 (ja)	2019-11-22	2025-10-30	メディミューンリミテッド	Ｅ２ユビキチン又はユビキチン様コンジュゲートドメインを含む融合タンパク質並びに特定のタンパク質分解のためのドメインの標的化
CN115916817A (zh)	2019-12-06	2023-04-04	朱诺治疗学股份有限公司	针对bcma靶向结合结构域的抗独特型抗体及相关组合物和方法
KR20220122656A (ko)	2019-12-06	2022-09-02	주노 쎄러퓨티크스 인코퍼레이티드	Ｇｐｒｃ5ｄ-표적화 결합 도메인에 대한 항-이디오타입 항체 및 관련 조성물 및 방법
AU2020402752A1 (en)	2019-12-12	2022-06-30	The United States Of America, As Represented By The Secretary, Department Of Health And Human Services	Antibody-drug conjugates specific for CD276 and uses thereof
WO2021119505A1 (en)	2019-12-13	2021-06-17	Genentech, Inc.	Anti-ly6g6d antibodies and methods of use
MY202559A (en)	2019-12-27	2024-05-08	Chugai Pharmaceutical Co Ltd	Anti-ctla-4 antibody and use thereof
CN116234829A (zh)	2020-01-03	2023-06-06	马伦戈治疗公司	抗tcr抗体分子及其用途
CN110818795B (zh)	2020-01-10	2020-04-24	上海复宏汉霖生物技术股份有限公司	抗tigit抗体和使用方法
CN118949063A (zh)	2020-01-22	2024-11-15	上海森辉医药有限公司	艾日布林衍生物的药物偶联物、其制备方法及其在医药上的应用
WO2022050954A1 (en)	2020-09-04	2022-03-10	Genentech, Inc.	Dosing for treatment with anti-tigit and anti-pd-l1 antagonist antibodies
WO2021194481A1 (en)	2020-03-24	2021-09-30	Genentech, Inc.	Dosing for treatment with anti-tigit and anti-pd-l1 antagonist antibodies
TWI895351B (zh)	2020-02-12	2025-09-01	日商中外製藥股份有限公司	用於癌症之治療的抗cd137抗原結合分子
AU2021236306A1 (en)	2020-03-13	2022-09-15	Genentech, Inc.	Anti-interleukin-33 antibodies and uses thereof
TWI867190B (zh)	2020-03-19	2024-12-21	美商建南德克公司	同功型選擇性抗-TGF-β抗體及其使用方法
BR112022019042A2 (pt)	2020-03-25	2022-11-01	Jiangsu Hengrui Pharmaceuticals Co Ltd	Método de preparação para conjugado anticorpo-fármaco
JP7689979B2 (ja)	2020-03-25	2025-06-09	江蘇恒瑞医薬股▲ふん▼有限公司	抗体薬物複合体を含む医薬組成物及びその使用
EP4127724A1 (de)	2020-04-03	2023-02-08	Genentech, Inc.	Therapeutische und diagnostische verfahren für krebs
CN115916822A (zh)	2020-04-24	2023-04-04	基因泰克公司	使用抗CD79b免疫缀合物的方法
EP4143345A1 (de)	2020-04-28	2023-03-08	Genentech, Inc.	Verfahren und zusammensetzungen zur immuntherapie gegen nicht-kleinzelligen lungenkrebs
WO2021231976A1 (en)	2020-05-14	2021-11-18	Xencor, Inc.	Heterodimeric antibodies that bind prostate specific membrane antigen (psma) and cd3
WO2021248133A1 (en)	2020-06-05	2021-12-09	Codiak Biosciences, Inc.	Anti-transferrin extracellular vesicles
IL298878A (en)	2020-06-11	2023-02-01	Genentech Inc	Nanolipoprotein-polypeptide conjugates and compositions, systems, and methods using same
WO2021252977A1 (en)	2020-06-12	2021-12-16	Genentech, Inc.	Methods and compositions for cancer immunotherapy
CN115916348A (zh)	2020-06-18	2023-04-04	基因泰克公司	使用抗tigit抗体和pd-1轴结合拮抗剂的治疗
CA3188000A1 (en)	2020-07-13	2022-01-20	Genentech, Inc.	Cell-based methods for predicting polypeptide immunogenicity
JP7846667B2 (ja)	2020-07-16	2026-04-15	レジェンドバイオテックアイルランドリミテッド	Ｃｄ２０結合分子及びその使用
JPWO2022025184A1 (de)	2020-07-29	2022-02-03
WO2022029660A1 (en)	2020-08-05	2022-02-10	Juno Therapeutics, Inc.	Anti-idiotypic antibodies to ror1-targeted binding domains and related compositions and methods
CR20230119A (es)	2020-08-07	2023-05-16	Genentech Inc	Proteínas de fusión del ligando para flt3 y métodos de uso
CN115836122A (zh)	2020-08-07	2023-03-21	基因泰克公司	用于预测多肽免疫原性的基于t细胞的方法
WO2022056490A1 (en)	2020-09-14	2022-03-17	Vor Biopharma, Inc.	Chimeric antigen receptors for treatment of cancer
KR20230082632A (ko)	2020-10-05	2023-06-08	제넨테크, 인크.	항-fcrh5/항-cd3 이중특이성 항체를 사용한 치료를 위한 투약
WO2022093745A1 (en)	2020-10-26	2022-05-05	The United States Of America, As Represented By The Secretary, Department Of Health And Human Services	Single domain antibodies targeting sars coronavirus spike protein and uses thereof
CA3199623A1 (en)	2020-10-27	2022-05-05	Vor Biopharma Inc.	Compositions and methods for treating hematopoietic malignancy
AU2021374594B2 (en)	2020-11-04	2026-03-05	Genentech, Inc.	Dosing for treatment with anti-cd20/anti-cd3 bispecific antibodies and anti-cd79b antibody drug conjugates
CA3196539A1 (en)	2020-11-04	2022-05-12	Chi-Chung Li	Dosing for treatment with anti-cd20/anti-cd3 bispecific antibodies
KR20230100732A (ko)	2020-11-04	2023-07-05	제넨테크, 인크.	항-cd20/항-cd3 이중특이성 항체의 피하 투여
WO2022115865A2 (en)	2020-11-25	2022-06-02	Xilio Development, Inc.	Tumor-specific cleavable linkers
WO2022116877A1 (en)	2020-12-02	2022-06-09	Shanghai Henlius Biotech, Inc.	ANTI-GARP/TGFβ ANTIBODIES AND METHODS OF USE
JP7326584B2 (ja)	2020-12-17	2023-08-15	エフ・ホフマン－ラ・ロシュ・アクチェンゲゼルシャフト	抗ｈｌａ－ｇ抗体及びその使用
UY39610A (es)	2021-01-20	2022-08-31	Abbvie Inc	Conjugados anticuerpo-fármaco anti-egfr
US20240059789A1 (en)	2021-01-28	2024-02-22	Janssen Biotech, Inc.	Psma binding proteins and uses thereof
EP4301781A1 (de)	2021-03-01	2024-01-10	Xilio Development, Inc.	Kombination von maskierten ctla4 und pd1/pdl1-antikörpern zur behandlung von krebs
WO2022187270A1 (en)	2021-03-01	2022-09-09	Xilio Development, Inc.	Combination of ctla4 and pd1/pdl1 antibodies for treating cancer
US20240158503A1 (en)	2021-03-03	2024-05-16	Pierre Fabre Medicament	Anti-vsig4 antibody or antigen binding fragment and uses thereof
JP2024511319A (ja)	2021-03-09	2024-03-13	ゼンコアインコーポレイテッド	Ｃｄ３及びｃｌｄｎ６に結合するヘテロ二量体抗体
JP2024509274A (ja)	2021-03-10	2024-02-29	ゼンコアインコーポレイテッド	Ｃｄ３及びｇｐｃ３に結合するヘテロ二量体抗体
AR125344A1 (es)	2021-04-15	2023-07-05	Chugai Pharmaceutical Co Ltd	Anticuerpo anti-c1s
US20240218055A1 (en)	2021-04-29	2024-07-04	The U.S.A., As Represented By The Secretary, Department Of Health And Human Services	Lassa virus-specific nanobodies and methods of their use
MX2023012699A (es)	2021-04-30	2023-11-21	Hoffmann La Roche	Dosificacion para el tratamiento con anticuerpo biespecifico anti-cd20/anti-cd3.
CA3213632A1 (en)	2021-04-30	2022-11-03	F. Hoffmann-La Roche Ag	Dosing for combination treatment with anti-cd20/anti-cd3 bispecific antibody and anti-cd79b antibody drug conjugate
TW202309088A (zh)	2021-04-30	2023-03-01	法商皮爾法伯製藥公司	新的穩定抗ｖｉｓｔａ抗體
KR20240007184A (ko)	2021-05-12	2024-01-16	제넨테크, 인크.	미만성 거대 b세포 림프종을 치료하기 위해 항-cd79b 면역접합체를 사용하는 방법
WO2022244838A1 (ja)	2021-05-19	2022-11-24	中外製薬株式会社	分子のｉｎｖｉｖｏ薬物動態を予測する方法
EP4347656A1 (de)	2021-05-28	2024-04-10	GlaxoSmithKline Intellectual Property Development Limited	Kombinationstherapien zur behandlung von krebs
US20240270853A1 (en)	2021-06-04	2024-08-15	Chugai Seiyaku Kabushiki Kaisha	Anti-ddr2 antibodies and uses thereof
US20240270851A1 (en)	2021-06-09	2024-08-15	The U.S.A., As Represented By The Secretary, Department Of Health And Human Services	Cross species single domain antibodies targeting pd-l1 for treating solid tumors
TWI864408B (zh)	2021-06-25	2024-12-01	日商中外製藥股份有限公司	抗ctla-4抗體的用途
AU2022299846B2 (en)	2021-06-25	2024-08-15	Chugai Seiyaku Kabushiki Kaisha	Anti–ctla-4 antibody
US11807685B2 (en)	2021-08-05	2023-11-07	The Uab Research Foundation	Anti-CD47 antibody and uses thereof
US20240336697A1 (en)	2021-08-07	2024-10-10	Genentech, Inc.	Methods of using anti-cd79b immunoconjugates to treat diffuse large b-cell lymphoma
US20240342282A1 (en)	2021-08-13	2024-10-17	Ludwig-Maximilians-Universität München	Anti-csf1r car expressing lymphocytes for targeted tumor therapy
MX2024002476A (es)	2021-08-27	2024-05-20	Janssen Biotech Inc	Anticuerpos anti-psma y usos de estos.
JP2024532537A (ja)	2021-09-06	2024-09-05	ヴェラクサバイオテックゲーエムベーハー	真核生物における遺伝暗号の拡張のための新規アミノアシルｔＲＮＡ合成酵素変異体
TW202321308A (zh)	2021-09-30	2023-06-01	美商建南德克公司	使用抗ｔｉｇｉｔ抗體、抗ｃｄ３８抗體及ｐｄ—１軸結合拮抗劑治療血液癌症的方法
EP4412713A1 (de)	2021-10-05	2024-08-14	GlaxoSmithKline Intellectual Property Development Ltd	Kombinationstherapien zur behandlung von krebs
TW202333781A (zh)	2021-10-08	2023-09-01	日商中外製藥股份有限公司	抗ｈｌａ－ｄｑ２﹒５抗體製劑
CN117980327A (zh)	2021-11-03	2024-05-03	杭州多禧生物科技有限公司	抗体的特异性偶联
KR20240102971A (ko)	2021-11-16	2024-07-03	제넨테크, 인크.	모수네투주맙을 이용하여 전신 홍반성 루푸스(sle)를 치료하기 위한 방법과 조성물
ES3039688T3 (en)	2021-11-25	2025-10-23	Veraxa Biotech Gmbh	Improved antibody-payload conjugates (apcs) prepared by site-specific conjugation utilizing genetic code expansion
CA3238627A1 (en)	2021-11-25	2023-06-01	Christine Kohler	Improved antibody-payload conjugates (apcs) prepared by site-specific conjugation utilizing genetic code expansion
KR20240119102A (ko)	2021-12-08	2024-08-06	유럽피안 몰레큘러 바이올로지 래보러토리	표적화 접합체의 제조를 위한 친수성 테트라진-관능화 페이로드
CN118488965A (zh)	2021-12-17	2024-08-13	上海复宏汉霖生物技术股份有限公司	抗ox40抗体、多特异性抗体及其使用方法
JP2025501522A (ja)	2021-12-17	2025-01-22	シャンハイ・ヘンリウス・バイオテック・インコーポレイテッド	抗ｏｘ４０抗体及び使用方法
UY40097A (es)	2022-01-07	2023-07-14	Johnson & Johnson Entpr Innovation Inc	Materiales y métodos de proteínas de unión a il-1b
EP4372000A3 (de)	2022-02-15	2024-07-17	Tagworks Pharmaceuticals B.V.	Maskiertes il12-protein
WO2023180353A1 (en)	2022-03-23	2023-09-28	F. Hoffmann-La Roche Ag	Combination treatment of an anti-cd20/anti-cd3 bispecific antibody and chemotherapy
JP2025514610A (ja)	2022-03-25	2025-05-09	シャンハイ・ヘンリウス・バイオテック・インコーポレイテッド	抗ｍｓｌｎ抗体及び使用方法
IL315770A (en)	2022-04-01	2024-11-01	Genentech Inc	Dosage for treatment with bispecific anti-FCRH5/anti-CD3 antibodies
CN119013300A (zh)	2022-04-13	2024-11-22	豪夫迈·罗氏有限公司	抗cd20/抗cd3双特异性抗体的药物组合物和使用方法
TWI882313B (zh)	2022-04-13	2025-05-01	美商建南德克公司	治療性蛋白質之醫藥組成物及使用方法
WO2023215293A1 (en)	2022-05-02	2023-11-09	Athanor Biosciences, Inc.	Cancer eradicating – bio-nanoparticles (ce-bnp)
CN119317641A (zh)	2022-05-11	2025-01-14	基因泰克公司	针对用抗fcrh5/抗cd3双特异性抗体进行治疗的给药
EP4537107A2 (de)	2022-06-07	2025-04-16	Genentech, Inc.	Verfahren zur bestimmung der wirksamkeit einer lungenkrebsbehandlung mit einem anti-pd-l1-antagonisten und einem anti-tigit-antagonisten-antikörper
JP2025523020A (ja)	2022-07-13	2025-07-17	ジェネンテック，インコーポレイテッド	抗ＦｃＲＨ５／抗ＣＤ３二重特異性抗体による処置のための投与
CA3261510A1 (en)	2022-07-19	2024-01-25	F. Hoffmann-La Roche Ag	DOSAGE FOR TREATMENT WITH BISOPECIFIC ANTI-FCRH5/ANTI-CD3 ANTIBODIES
CA3261989A1 (en)	2022-07-22	2024-01-25	Genentech, Inc.	ANTI-STEAP1 ANTIGEN-BINDING MOLECULES AND THEIR USES
JP2025531738A (ja)	2022-09-01	2025-09-25	ジェネンテック，インコーポレイテッド	膀胱がんの治療方法及び診断方法
WO2024073751A1 (en)	2022-09-29	2024-04-04	Vor Biopharma Inc.	Methods and compositions for gene modification and enrichment
IL320221A (en)	2022-10-12	2025-06-01	Tagworks Pharmaceuticals B V	Strained bicyclo-nonanes
AU2023370106A1 (en)	2022-10-25	2025-05-08	Fundació Privada Institut D'investigació Oncològica De Vall Hebron	Combination therapy for the treatment of cancer
WO2024091991A1 (en)	2022-10-25	2024-05-02	Genentech, Inc.	Therapeutic and diagnostic methods for multiple myeloma
WO2024102948A1 (en)	2022-11-11	2024-05-16	Celgene Corporation	Fc receptor-homolog 5 (fcrh5) specific binding molecules and bispecific t-cell engaging antibodies including same and related methods
CN120712102A (zh)	2022-12-13	2025-09-26	朱诺治疗学股份有限公司	对baff-r和cd19具特异性的嵌合抗原受体及其方法和用途
GB202219154D0 (en)	2022-12-19	2023-02-01	Metacurum Biotech Ab	Antibodies and uses thereof
CN120569216A (zh)	2023-01-20	2025-08-29	巴斯夫欧洲公司	稳定型生物聚合物组合物、其制造和用途
WO2024168312A1 (en)	2023-02-09	2024-08-15	Vor Biopharma Inc.	Methods for treating hematopoietic malignancy
KR20250169530A (ko)	2023-03-10	2025-12-03	태그웍스 파마슈티컬스 비.브이.	개선된 t-링커를 갖는 트랜스-사이클로옥텐
WO2024218345A1 (en)	2023-04-21	2024-10-24	Glaxosmithkline Intellectual Property Development Limited	Cytotoxicity targeting chimeras for antibody-drug conjugates and bispecific antibodies
WO2024233341A1 (en)	2023-05-05	2024-11-14	Genentech, Inc.	Dosing for treatment with anti-fcrh5/anti-cd3 bispecific antibodies
KR20260020418A (ko)	2023-06-07	2026-02-11	펀다시오 프리바다 인스티튜트 드인베스티가시오 온콜로지카 데 발 헤브론	Braf 저해제를 이용한 암 치료용 조합 요법
TW202513088A (zh)	2023-06-07	2025-04-01	瓦爾希伯倫私人腫瘤研究基金會	用於治療癌症的與ｍｅｋ抑制劑的組合療法
EP4473974A1 (de)	2023-06-07	2024-12-11	Peptomyc, S.L.	Omomyc und kras-hemmern kombinationstherapie zur behandlung von krebs
CN121285742A (zh)	2023-06-08	2026-01-06	基因泰克公司	用于淋巴瘤的诊断和治疗方法的巨噬细胞特征
EP4727971A1 (de)	2023-06-13	2026-04-22	Adcentrx Therapeutics Inc.	Verfahren und zusammensetzungen im zusammenhang mit antikörpern und antikörper-wirkstoff-konjugaten (adcs) zur bindung von nectin-4-proteinen
US12319747B2 (en)	2023-07-03	2025-06-03	Medicovestor, Inc.	Methods of using anti-SP17 immunotherapeutics
AU2024295016A1 (en)	2023-07-20	2026-02-05	The United States Of America, As Represented By The Secretary, Department Of Health And Human Services	Fully human monoclonal antibodies and chimeric antigen receptors against cd276 for the treatment of solid tumors
AU2024300552A1 (en)	2023-07-27	2026-01-29	Veraxa Biotech Gmbh	Hydrophilic trans-cyclooctene (hytco) compounds, constructs and conjugates containing the same
EP4509142A1 (de)	2023-08-16	2025-02-19	Ona Therapeutics S.L.	Fgfr4 als target in der krebsbehandlung
WO2025056807A1 (en)	2023-09-15	2025-03-20	Basf Se	Stabilized biopolymer composition, their manufacture and use
US12364777B2 (en)	2023-10-20	2025-07-22	Medicovestor, Inc.	Homodimeric antibodies for use in treating cancers and methods of use
WO2025106474A1 (en)	2023-11-14	2025-05-22	Genentech, Inc.	Therapeutic and diagnostic methods for treating cancer with anti-fcrh5/anti-cd3 bispecific antibodies
US12600795B2 (en)	2023-12-26	2026-04-14	Medicovestor, Inc.	Oligomeric IgG for immunotherapeutics and diagnostics
US12116410B1 (en)	2023-12-26	2024-10-15	Medicovestor, Inc.	Methods of manufacturing dimeric antibodies
US12378314B1 (en)	2024-02-02	2025-08-05	Medicovestor, Inc.	Proteins that bind folate receptor alpha including fully-human antibodies
US12258396B1 (en)	2024-02-02	2025-03-25	Medicovestor, Inc.	Methods of using immunotherapeutics that bind folate receptor alpha
US12240900B1 (en)	2024-02-02	2025-03-04	Medicovestor, Inc.	Nucleic acids, vectors, and cells that encode antibodies and other proteins that bind folate receptor alpha
WO2025171238A1 (en)	2024-02-07	2025-08-14	The United States Of America, As Represented By The Secretary, Department Of Health And Human Services	Monoclonal antibodies that bind the juxta-membrane region of mesothelin and uses thereof
WO2025174248A1 (en)	2024-02-16	2025-08-21	Tagworks Pharmaceuticals B.V.	Trans-cyclooctenes with "or gate" release
WO2025264533A1 (en)	2024-06-17	2025-12-26	Adcentrx Therapeutics Inc.	Methods and compositions related to antibody drug conjugates (adcs) that bind steap-1 proteins
WO2026030464A1 (en)	2024-07-30	2026-02-05	Genentech, Inc.	Dosage regimen for reducing cytokine release syndrome (crs) with anti-fcrh5/anti-cd3 bispecific antibodies in multiple myeloma therapy
WO2026043376A1 (en)	2024-08-22	2026-02-26	Tagworks Pharmaceuticals B.V.	Trans-cyclooctene formulations
WO2026078060A1 (en)	2024-10-08	2026-04-16	Basf Se	Tocopherol alkoxylates for biopolymer stabilization

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US5053394A (en) *	1988-09-21	1991-10-01	American Cyanamid Company	Targeted forms of methyltrithio antitumor agents
EP0329184A3 (de) *	1988-02-19	1990-05-23	Neorx Corporation	Antimere und antimere Konjugation
US5006652A (en) *	1988-08-08	1991-04-09	Eli Lilly And Company	Intermediates for antibody-vinca drug conjugates
US5028697A (en) *	1988-08-08	1991-07-02	Eli Lilly And Company	Cytotoxic antibody conjugates of hydrazide derivatized methotrexate analogs via simple organic linkers
US5094849A (en) *	1988-08-08	1992-03-10	Eli Lilly And Company	Cytotoxic antibody conjugates of hydrazide derivatized vinca analogs via simple organic linkers
US5144012A (en) *	1988-08-08	1992-09-01	Eli Lilly And Company	Cytotoxic drug conjugates
US5045451A (en) *	1988-10-26	1991-09-03	Board Of Regents	Methods for screening antibodies for use as immunotoxins
IL115770A (en) *	1989-04-14	1999-03-12	American Cyanamid Co	Substituted disulfides of formula q-sp-ss-w their preparation and use for inhibiting the growth of tumours and for treating bacterial infections
GB8928874D0 (en) *	1989-12-21	1990-02-28	Celltech Ltd	Humanised antibodies
GB9120467D0 (en) *	1991-09-26	1991-11-06	Celltech Ltd	Anti-hmfg antibodies and process for their production
US5773001A (en) *	1994-06-03	1998-06-30	American Cyanamid Company	Conjugates of methyltrithio antitumor agents and intermediates for their synthesis

1994
- 1994-06-03 US US08/253,877 patent/US5773001A/en not_active Expired - Lifetime
- 1994-10-12 TW TW083109420A patent/TW394778B/zh not_active IP Right Cessation
1995
- 1995-05-26 US US08/452,164 patent/US5877296A/en not_active Expired - Lifetime
- 1995-05-31 JP JP15564495A patent/JP3650165B2/ja not_active Expired - Lifetime
- 1995-06-01 CA CA2150785A patent/CA2150785C/en not_active Expired - Lifetime
- 1995-06-01 DE DE69528016T patent/DE69528016T2/de not_active Expired - Lifetime
- 1995-06-01 AT AT95303746T patent/ATE223234T1/de active
- 1995-06-01 EP EP95303746A patent/EP0689845B1/de not_active Expired - Lifetime
- 1995-06-01 ES ES95303746T patent/ES2181752T3/es not_active Expired - Lifetime
- 1995-06-01 SI SI9530554T patent/SI0689845T1/xx unknown
- 1995-06-01 IL IL11398495A patent/IL113984A/xx not_active IP Right Cessation
- 1995-06-01 PT PT95303746T patent/PT689845E/pt unknown
- 1995-06-01 DK DK95303746T patent/DK0689845T3/da active
- 1995-06-02 FI FI952720A patent/FI117690B/fi not_active IP Right Cessation
- 1995-06-02 AU AU20449/95A patent/AU697280B2/en not_active Expired
- 1995-06-02 NZ NZ536440A patent/NZ536440A/en not_active IP Right Cessation
- 1995-06-02 NZ NZ272274A patent/NZ272274A/en not_active IP Right Cessation
- 1995-06-02 NO NO19952206A patent/NO313617B1/no not_active IP Right Cessation
- 1995-06-02 ZA ZA954570A patent/ZA954570B/xx unknown
- 1995-06-03 KR KR1019950014699A patent/KR100408376B1/ko not_active Expired - Lifetime
- 1995-06-05 US US08/462,939 patent/US5767285A/en not_active Expired - Lifetime
- 1995-06-05 US US08/461,284 patent/US5739116A/en not_active Expired - Lifetime
1997
- 1997-05-14 BR BR1100990-0A patent/BR1100990A/pt active IP Right Grant
- 1997-05-14 BR BR1101078-9A patent/BR1101078A/pt active IP Right Grant
- 1997-09-17 NZ NZ328762A patent/NZ328762A/xx not_active IP Right Cessation
2003
- 2003-01-27 CY CY0300005A patent/CY2334B1/xx unknown
2005
- 2005-01-12 JP JP2005004986A patent/JP2005139200A/ja active Pending

Also Published As

Publication number	Publication date
EP0689845B1 (de)	2002-09-04
NO952206D0 (no)	1995-06-02
IL113984A (en)	2000-09-28
US5739116A (en)	1998-04-14
IL113984A0 (en)	1995-10-31
CA2150785C (en)	2010-07-06
JP3650165B2 (ja)	2005-05-18
ATE223234T1 (de)	2002-09-15
FI952720L (fi)	1995-12-04
KR100408376B1 (ko)	2004-03-09
SI0689845T1 (en)	2002-12-31
US5767285A (en)	1998-06-16
CA2150785A1 (en)	1995-12-04
BR1101078A (pt)	1999-10-26
US5877296A (en)	1999-03-02
FI117690B (fi)	2007-01-31
NZ328762A (en)	2000-08-25
BR1100990A (pt)	2002-04-02
NO313617B1 (no)	2002-11-04
DK0689845T3 (da)	2003-01-06
CY2334B1 (en)	2004-02-06
US5773001A (en)	1998-06-30
DE69528016D1 (de)	2002-10-10
NZ272274A (en)	1997-11-24
AU2044995A (en)	1995-12-14
PT689845E (pt)	2002-12-31
NZ536440A (en)	2007-08-31
JP2005139200A (ja)	2005-06-02
TW394778B (en)	2000-06-21
AU697280B2 (en)	1998-10-01
ES2181752T3 (es)	2003-03-01
NO952206L (no)	1995-12-04
EP0689845A3 (de)	1999-08-25
JPH0848637A (ja)	1996-02-20
FI952720A0 (fi)	1995-06-02
KR960000234A (ko)	1996-01-25
DE69528016T2 (de)	2003-01-02
EP0689845A2 (de)	1996-01-03

Publication	Publication Date	Title
CY2334B1 (en)	2004-02-06	Conjugates of methyltrithio antitumor agents and intermediates for their synthesis.
UY23541A1 (es)	1993-06-28	Procedimiento para la preparacion de conjugados de tioeter
IL189629A0 (en)	2008-06-05	Compositions containing human ctla-4 antibodies
CY2355B1 (en)	2004-06-04	Method for the preparation of monomeric calicheamicin derivative/carrier conjugates.
WO2002022851A3 (en)	2003-05-01	Novel tumor-associated marker
CA2295936A1 (en)	1999-01-21	Chimeric interleukin-6 soluble receptor/ligand protein, analogs thereof and uses thereof
NZ270659A (en)	1997-08-22	Mammalian protein which binds to a gst-fkbp-rapamycin complex, dna therefor and diagnostic compositions
AU1125192A (en)	1993-01-28	Fusion proteins for prodrug activation, the preparation and use thereof
AU634280B2 (en)	1993-02-18	Anticoagulant peptides
AU633069B2 (en)	1993-01-21	Targeted forms of methyltrithio antitumor agents
YU10599A (sh)	2001-07-10	Amorfni benzotiofeni, postupak dobijanja istih i njihova farmaceutska formulacija
CA2310778A1 (en)	1999-06-03	Intermediates and methods useful in the semisynthesis of paclitaxel and analogs
AU5298696A (en)	1996-10-08	Tumor marker protein for cancer risk assessment
EA200000705A1 (ru)	2000-12-25	Промежуточные соединения и способ синтеза 17-замещенных 16.бета.-арилокси 4-азастероидов
LT2341B (lt)	1993-12-15	N,n'-di(etilenimido)-fosforo arba tiofosforo rugsties amidu gavimo budas
BR1100104A (pt)	2000-08-01	Anticorpos monoclonais para fator de maturação de linfócito citotóxico